Document:

Supply Agreement

 Exhibit 10.13 
 SUPPLY AGREEMENT 
 THIS
SUPPLY AGREEMENT, together with exhibits attached hereto (the “Agreement”), effective as of March 20, 2009 (the “Effective Date”), is entered into by and between BG
MEDICINE, INC., organized under the laws of Delaware and having its principal place of business at 610 N. Lincoln Street, Waltham, MA 02451 (“BG Medicine”), and CORGENIX
INC., organized under the laws of Delaware and having its principal place of business at 11575 Main Street, Suite 400, Broomfield, Colorado 80020 (“Corgenix”). BG Medicine and Corgenix may each be referred to
herein individually as a “Party” or, collectively, as “Parties.” 
 RECITALS

 WHEREAS, BG Medicine has technology and intellectual property related to certain
novel biomarkers and innovative molecular diagnostic products; and 
 WHEREAS, Corgenix is
engaged in the business of developing, manufacturing and supporting diagnostic tests and related products; and 
 WHEREAS, BG Medicine and Corgenix wish to enter into an agreement under which Corgenix will manufacture and supply BG Medicine, or its designees, with certain microtiter plate ELISA in vitro
diagnostic test kits, as set forth in more detail herein, subject to the terms and conditions set forth herein. 
 NOW THEREFORE, in consideration of the promises and undertakings set forth herein, the Parties agree as follows: 
 ARTICLE 1 
 DEFINITIONS

 Capitalized terms not otherwise defined herein will have the meaning set forth below: 
 1.1 “Affiliates” means, with respect to Party, any person or entity controlling, controlled by, or under common control
with such Party. For the purposes of this Section 1.1 only, “control” means (a) the possession, directly or indirectly, of the power to direct the management or policies of a Person, whether through the ownership of voting
securities, by contract or otherwise, or (b) the ownership, directly or indirectly, of at least fifty percent (50%) (or, if less, the maximum ownership interest permitted by law) of the voting securities or other ownership interest of a
Person; provided that, if local law requires a minimum percentage of local ownership in excess of fifty percent (50%), then control will be established by direct or indirect beneficial ownership of one hundred percent (100%) of the maximum
ownership percentage that may, under such local law, be owned by foreign interests. 
 1.2 “Authorized
Representative” shall have the meaning set forth in Directive 98/79/EC. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.3 “BG Medicine Technology” means the BG Medicine Patent Rights and BG
Medicine Know-How, as defined below: 
 (a) “BG Medicine Patent Rights” means any and all Patent Rights
covering the BG Medicine Know-How. 
 (b) “BG Medicine Know-How” means the information, data, skills,
processes, methods, know-how, trade secrets and experience, including, without limitation, formulas and specifications, whether patentable or not, that are Controlled by BG Medicine at anytime during the Term and that are necessary for Corgenix in
order to use the Critical Components solely in the manufacture of Products under this Agreement. 
 1.4 “CE
Marking” means the certification and marking required by the European Commission for marketing and sales of in vitro diagnostic medical devices in the European Union, as set forth in Directive 98/79/EC and any and all other
applicable laws or regulations. 
 1.5 “Certificate of Analysis” means a certificate of analysis signed and
dated by a Corgenix employee qualified and duly authorized to certify that each lot of product released for distribution was manufactured in compliance with approved procedures and that all specifications have been met. The specifications and the
results obtained with the lot of product being certified shall be included on the certificate. An example of a Certificate of Analysis is shown in Exhibit B, but the exact contents and format will be modified to reflect final product specifications.

 1.6 “Certificate of Nonconformance” means a certificate of analysis signed and dated by a BG Medicine
employee qualified and duly authorized to certify that the results of assays conducted on an indicated shipment of Products hereunder do not conform to the Specifications therefor and indicating the reason(s) for non-conformance. The Certificate of
Nonconformance shall include without limitation a description of the pertinent assay(s) conducted, the date on which it was (they were) conducted, and the results of the assay(s). 
 1.7 “Confidential Information” means any proprietary information, technical data, trade secrets or know-how, including, but
not limited to, research, product plans, products, services, customers, customer lists, markets, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing,
finances or other business information disclosed by the disclosing party directly or indirectly in writing, orally, or by drawings. 
 1.8 “Control” means, with respect to any information or an intellectual property right, possession of the ability, whether arising by ownership or license, to grant a license or sublicense as provided for herein under such
information or right without violating the terms of any written agreement with any Third Party. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.9 “Corgenix Technology” means the Corgenix Patent Rights and Corgenix
Know-How, as defined below: 
 (a) “Corgenix Patent Rights” means any and all Patent Rights covering the
Corgenix Know-How. 
 (b) “Corgenix Know-How” means the information, data, skills, processes, methods,
know-how, trade secrets and experience, including, without limitation, formulas and specifications, whether patentable or not, that are unique to and Controlled by Corgenix at anytime during the Term and used in the manufacture of Products under
this Agreement. 
 1.10 “Critical Components” means those certain materials specified in Exhibit E attached
hereto. 
 1.11 “Directive 98/79/EC” means Directive 98/79/EC of the European Parliament and of the Council of
27 October 1998 on in vitro medical devices, as set forth in the Official Journal of the European Communities, L 331, July 12, 1998. 
 1.12 “FDA” means the United States Food and Drug Administration and any successor agency thereto. 
 1.13 “Inventory Release Order” shall have the meaning assigned to it in Section 2.6(d). 
 1.14 “Lot” means a particular manufacturing run of Products. 
 1.15 “Lyophilizer” means the capital equipment as described in Exhibit K. 
 1.16 “Patent
Right” means: (i) all issued and existing patents, including any extensions, supplemental protection certificates, registrations, confirmations, reissues, reexaminations or renewals thereof; and (ii) all pending applications,
including any provisional applications, converted provisional applications, continuing prosecution applications and continuation, divisional, or continuation-in-part applications thereof, for any of the foregoing. 
 1.17 “Pilot Lot” shall have the meaning assigned to it in Section 4.2(a). 
 1.18 “Products” shall mean the items set forth on Exhibit A, as may be amended from time to time in writing by the Parties.

 1.19 “Purchase Order” shall have the meaning assigned to it in Section 2.6(b). 
 1.20 “Specification” means the written specifications for the Products to be manufactured and supplied under this
Agreement, as set forth in documents supplied by BG Medicine that are approved and modified solely by mutual written agreement of the Parties in accordance with this Agreement. 
 1.21 “Term” shall have the meaning set forth in Section 9.1. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.22 “Third Party” means any person or entity other than Corgenix, BG
Medicine, or Affiliates of either. 
 1.23 “Transfer Price” shall mean with respect to each Product, the price
set forth in Exhibit D as of the Effective Date, as subsequently modified solely in accordance with Article 4 and Section 2.6 of this Agreement. 
 ARTICLE 2 
 SUPPLY 
 2.1 Terms and Conditions. All supply of Products by Corgenix to BG Medicine or its designees shall be subject to the terms and
conditions of this Agreement. ANY TERMS OR CONDITIONS OF ANY PURCHASE ORDER OR ACKNOWLEDGMENT GIVEN OR RECEIVED WHICH ARE ADDITIONAL TO OR INCONSISTENT WITH THIS AGREEMENT SHALL HAVE NO EFFECT AND SUCH TERMS AND CONDITIONS ARE HEREBY EXCLUDED AND
REJECTED. 
 2.2 Start-Up. 
 (a) General. In consideration for the payment set forth in Section 4.1(a) and further defined in Exhibit C, Corgenix shall perform any and all tasks reasonably necessary to prepare for
supplying Products under this Agreement, including, without limitation, developing manufacturing and quality control documentation, training, travel by Corgenix personnel to BG Medicine and/or Future Diagnostics as necessary for technology transfer,
and development of any and all necessary compliance documentation required by the FDA and the International Standards Organization (“ISO”) to allow timely market entry upon 510(k) clearance. The amount of such payments shall not
exceed 110% of the respective estimated amounts without receiving advance written approval for such higher fee from BG Medicine. 
 (b) CE-Marking. As Corgenix has the capability and know-how to provide CE-Marking services, BG Medicine, in its sole discretion, may or may not request of Corgenix that such CE Marking services be provided. If BG Medicine
requests these CE Marking services of Corgenix, then, in consideration for the payment set forth in Exhibit F, Corgenix shall use all commercially reasonable efforts to obtain CE Marking certification for any and all Products by performing the tasks
as set forth in Exhibit F, which Corgenix shall use all commercially reasonable efforts to complete within two weeks following completion of all tasks required to create the Technical File for Product. To the extent full services for CE Marking are
not requested, the fees will be adjusted accordingly. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 2.3 Supply of Products. 
 (a) Supply. Subject to BG Medicine’s supply of Critical Components pursuant to Section 2.6(f), Corgenix shall supply
Products to BG Medicine or its designees as set forth in this Article 2 and in partial consideration for the payments set forth in Section 4.2. 
 (b) Specifications. All Products supplied pursuant to Section 2.3(a) shall comply with all applicable Specifications. After the Effective Date, if BG Medicine changes in writing the
Specifications applicable to the product insert, labeling, or the addition of other languages thereon, then Corgenix shall implement such changes; provided, however, that BG Medicine shall pay Corgenix its actual cost to implement such changes,
including scrap costs, without any mark-up or other surcharges, provided, further, that Corgenix shall notify BG Medicine in advance and in writing of such costs and BG Medicine’s obligation to reimburse Corgenix for such costs shall be subject
to BG Medicine’s approval, in its sole discretion, of such costs in writing before Corgenix incurs any such costs. 
 2.4 Subsequent Agreements and Good Manufacturing Practices. 
 (a) The Parties agree that within thirty
(30) days of the Effective Date of this Agreement that they shall define in writing a validation plan to be attached as Exhibit L to this Agreement once finalized. 
 (b) Corgenix shall manufacture all Products under this Agreement in compliance with applicable current Good Manufacturing Practices and the Quality System Regulation for in vitro diagnostic
devices, as set forth in 21 Code of Federal Regulations Part 820 et seq.; and in compliance with all applicable requirements of Directive 98/79/EC for obtaining CE Marking of such Products. 
 (c) Corgenix shall ensure that all of its vendor relationships related to the manufacture of Products are in compliance with the
above requirements, as applicable. 
 (d) The Parties agree that within sixty (60) days of the Effective Date of
this Agreement they shall define in writing any additional responsibilities between the Parties in the form of a Quality Agreement to ensure substantial compliance with all applicable regulatory requirements as set forth above and to define the
responsibilities of each party for meeting these requirements. Such Quality Agreement will be attached as Exhibit M to this Agreement once finalized. 
 Corgenix will manufacture and test all BG Medicine Products in accordance with documents (e.g. procedures and specifications) supplied by BG Medicine. These documents will include the manufacturing procedures, testing procedures and
specifications. Changes to these documents shall be approved by BG Medicine as part of the Corgenix change control system. BG Medicine shall approve changes to any other Corgenix document that may affect the quality of BG Medicine products.

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Corgenix shall provide periodic reports summarizing quality metrics associated with the manufacture of BG
Medicine products. The content and frequency of the reports will be defined in the Quality Agreement referred to above. 
 All non-conformances
occurring within the Corgenix quality system that may affect the quality of BG Medicine products shall be approved by BG Medicine. Details concerning the approval of these non-conformances will be given in the Quality Agreement. 
 (e) Corgenix agrees to establish a document retention procedure such that required quality records and reports are retained for a
minimum of five (5) years from the date of Product transfer to BG Medicine. 
 (f) Notwithstanding anything to the
contrary in this Agreement, in the event that BG Medicine voluntarily or as required by the FDA, recalls, corrects, withdraws, or recovers (“Recall”) the Product because the Product is or is reasonably believed to be adulterated or
misbranded within the meaning of the United States Food, Drug and Cosmetic Act, as amended (“FDC”), all costs and expenses of such Recall shall be allocated between the Parties in accordance with each Party’s relative responsibility
for the cause of the Recall. However, in the event a Recall is necessary solely because the Product does not meet the warranty set forth in Section 2.8 hereunder or the Specifications, Recall Expenses shall be the full and sole responsibility
of Corgenix. 
 2.5 Forecasts. No later than [***] after the conclusion of the second Pilot Lot, BG Medicine shall
provide Corgenix with a written [***] rolling forecast (“Forecast”) of the quantities of each Product estimated by BG Medicine to be ordered from Corgenix under this Agreement for each calendar month. The Forecast shall be updated
at least every three (3) months until such time that both Parties agree that updating less frequently is acceptable. The Parties agree that the Forecast is [***] and shall be used by Corgenix for [***]. 
 2.6 Orders. 
 (a) Purchase Orders. During the Term, BG Medicine shall have the right to place a firm Purchase Order with Corgenix for Products, setting forth the quantity of kits to be manufactured by Corgenix during a specified period.
Corgenix shall accept any and all such Purchase Orders from BG Medicine for each Product to fulfill that portion for which it has sufficient Critical Components. Corgenix shall use its best efforts to fulfill all Purchase Orders within [***] after
receipt by Corgenix, but in no event later than [***] after such receipt, unless the Purchase Order received from BG Medicine expressly sets forth in writing a later completion date, in which event Corgenix shall fulfill the Purchase Order on such
later date. 
 (b) Form of Purchase Order. Within thirty (30) days after the Effective Date, the parties
shall mutually approve in writing a standard form of purchase order, attached hereto as Exhibit G, for use by BG Medicine in ordering Products hereunder (a “Purchase Order”), such

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
approval to not be unreasonably withheld. All of BG Medicine’s orders for Product shall be made pursuant to such written Purchase Order form. Corgenix shall notify BG Medicine in writing as
soon as possible, but at least within [***] from receipt of a Purchase Order if Corgenix will be unable to fill any amount(s) of such Purchase Order, provided that such notice will not waive any of the supply obligations of Corgenix hereunder.

 (c) Inventory Release Orders. If BG Medicine chooses to have Corgenix drop ship product to BG Medicine’s
customers, at least [***] before the date which BG Medicine requests kits to be removed from BG Medicine inventory at Corgenix and shipped to a customer, BG Medicine shall place a firm Inventory Release Order as described in Exhibit H, with Corgenix
for Products, setting forth the customer name, address and related information, the number of kits and lot of the Products to be shipped, the method of shipment including shipping account number(s), and the requested date of shipment. Corgenix shall
provide confirmation of order shipment details for each product shipment to BG Medicine on the date of shipment by e-mail or through the electronic interface mechanism referred to below. 
 (d) Form of Inventory Release Order. Within thirty (30) days after the Effective Date, the Parties shall mutually approve
in writing a standard form of inventory release order, attached hereto as Exhibit H (“Inventory Release Order”), for use by BG Medicine in providing to Corgenix specific shipping instructions for Products, such approval to not be
unreasonably withheld. All of BG Medicine’s instructions for Product shall be noted on such written Inventory Release Order form and shall provide for shipment in compliance with Section 2.9, and will include information related to
Corgenix’ handling charges, direct shipping costs and lot number tracking. Corgenix shall notify BG Medicine in writing within [***] after receipt of an Inventory Release Order if Corgenix will be unable to fill any amount(s) and delivery
date(s) of such Inventory Release Order, provided that such notice will not waive, modify or supersede any of Corgenix’ obligations under this Agreement. 
 (e) Electronic Interface. The parties agree to work together to develop an electronic interface to facilitate the processing of product orders between the entities. It is expected that this
interface will be in place no later than March 31, 2010. Details related to this interface will be agreed to by the parties no later than September 30, 2009. 
 (f) Supply of Critical Components. At the time BG Medicine wishes Corgenix to begin production of the Pilot Lots, BG Medicine shall supply Corgenix with a quantity of Critical Components
that BG Medicine, in its sole good faith estimation, believes will be sufficient to meet Corgenix’ needs for those Pilot Lots. BG Medicine may elect to provide certain Critical Components to Corgenix on a lot by lot basis during the Pilot Lot
phase. After the third Pilot Lot is completed, BG Medicine will supply Critical Components for the first three (3) months of production. BG Medicine may elect to provide Critical Components for the first three (3) months of production at
an earlier point, if initial Pilot Lots are successful. Corgenix shall request additional supplies of Critical Components in writing from BG Medicine at least [***] before Corgenix reasonably anticipates that it will need such supplies to fulfill BG

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Medicine’s orders for Products. Upon receipt by Corgenix of Critical Components, Corgenix shall perform sufficient incoming quality control (“iQC”) procedures, such
procedures are to be performed within [***] of material receipt in accordance with the Raw Material Specifications (RMS) developed with input and mutual agreement by both parties on such Critical Components to evaluate their suitability for use by
Corgenix under this Agreement. Corgenix shall notify BG Medicine in writing of the results of such iQC testing, whether positive or any deficiencies or defects in such Critical Components (the “iQC Notice”), including, without
limitation, a detailed description of such deficiencies or defects and the identity of the specific critical components with such deficiencies or defects. Corgenix shall, at BG Medicine’s request, return such Critical Components to BG Medicine
at BG Medicine’s expense within three (3) days after receiving such request. BG Medicine shall have the right to replace such Critical Components to the extent it agrees that a deficiency or defect exists. If BG Medicine disagrees with
Corgenix that such deficiency or defect exists, the Parties shall cooperate in good faith to evaluate such Critical Components and agree on whether they are acceptable for use by Corgenix under this Agreement. All Critical Components must have iQC
testing performed by Corgenix before used in manufacturing. If BG Medicine fails to receive an iQC Notice and Corgenix manufactures a Lot, Corgenix shall have no recourse or other remedy against BG Medicine arising from any failure, deficiency or
defect, of whatsoever kind or nature, relating to such Critical Components; unless, however, that Corgenix can show that proper iQC testing was conducted and the iQC Notice was not sent. Corgenix shall use any and all such Critical Components solely
in the manufacture by Corgenix of Products under this Agreement, and shall keep written records of the amounts used for each Lot. The Critical Components supplied by BG Medicine shall be free of charge to Corgenix; provided, however, that BG
Medicine shall retain sole ownership of the Critical Components at all times; and, provided further, that Corgenix shall use all commercially reasonable efforts to use one hundred percent (100%) of such Critical Components in Products supplied
to BG Medicine or its designees, and not to waste, discard, damage or destroy any such Critical Components other than wastage associated with normal manufacturing processes used by Corgenix under this Agreement, including, but not limited to, void
volume losses. BG Medicine shall have the right to audit Corgenix’ use of Critical Components supplied under this Agreement. 
 (g) Minimum Quantities. During each year commencing with the Effective Date, and each anniversary thereof during the Term, BG Medicine shall purchase minimum quantities of Products from Corgenix under this Agreement, as
follows: 
  

			
	 Year
	  	 Minimum Quantity

	 First Year (including Pilot Lot Volume)
	  	[***] kits
	 Second Year
	  	[***] kits
	 Third Year
	  	[***] kits

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 For purposes of this section for evaluating BG Medicine’s compliance with minimum
quantities, the annual one year period will commence with the date that the first pilot lot is certified to successfully meet the product specification. In addition, minimum quantities will be treated as aggregate minimum requirements. Once BG
Medicine purchases [***] kits from Corgenix, no further minimum quantity requirements will be in effect. 
 (h)
Minimum Lot Sizes. Minimum lot sizes for the Pilot Lots and the first Lot shall be [***] kits which Corgenix shall produce for BG Medicine under this Agreement. All lots after the Pilot Lots and such first Lot shall be a minimum [***]
kits, unless agreed otherwise by both Parties. 
 (i) New Product Codes. If BG Medicine wishes to introduce a new
product kit configuration, the Parties agree to implement such new configuration, and that Exhibits A and D will be amended accordingly. 
 2.7 Product Inspection. 
 (a) Product Release Criteria.
Corgenix shall perform all agreed upon procedures as documented in the manufacturing and quality release documents as further set forth in the Specifications for each Pilot Lot to ensure that each Pilot Lot is in compliance with all applicable
Specifications. In addition, Corgenix shall provide to BG Medicine kits from each Pilot Lot in a quantity sufficient, in BG Medicine’s sole good faith discretion, for BG Medicine to validate the Products independently. Corgenix shall not
provide Products made from the Pilot Lots to any Third Party, unless and until BG Medicine has determined, in its sole discretion, that such Products comply with any and all applicable Specifications. For each Lot after the Pilot Lots, Corgenix
shall use its best efforts to, within ten (10) days after such Lot is ready for testing, test each such Lot for compliance with any and all applicable Specifications. Corgenix shall promptly provide BG Medicine a Certificate of Analysis and
upon BG Medicine’s request any and all such test results and data (the “Test Results”) and kits from such Lot shall be provided to BG Medicine for the purpose of verifying such Test Results. The cost of the kits supplied to BG
Medicine for such verification shall be borne by BG Medicine. Notwithstanding anything in this Agreement to the contrary, Corgenix shall not provide any Product from any Lot to any Third Party unless and until Corgenix: (i) has supplied any and
all Test Results for such Lot to BG Medicine; and (ii) has received from BG Medicine written authorization to supply Products to Third Parties from such Lot (the “Release Criteria”). When BG Medicine has provided written
acceptance to Corgenix for each Lot verifying performance to the Specifications listed in the Certificate of Analysis, invoicing will occur per Section 2.12 and BG Medicine assumes ownership of the Lot at that time. 
 (b) Storage. If requested by BG Medicine, Corgenix shall perform stability tests on the Products to determine an appropriate
shelf life as detailed in Exhibit J. BG Medicine shall establish the product shelf life based on such stability tests, and if Corgenix has stored such Products properly under this Section 2.7(b), then BG Medicine shall bear the cost of
replacing

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
such Products if it desires such replacement. Corgenix shall store all Lots and Products under proper conditions at its facilities to maximize their life span and prevent failure, including,
without limitation, any storage criteria set forth in the Specifications. Since BG Medicine owns the completed Lots to be stored at Corgenix, BG Medicine shall insure such Lots and Products against accidental loss under a policy owned by BG
Medicine, until such time as such Lots or Products expire or are shipped in accordance with an Inventory Release Order from BG Medicine, whichever occurs earlier. Corgenix will notify BGM on a quarterly basis of the inventory available and the
remaining shelf life (“Inventory Report” as attached in Exhibit I). If any Lots or Products expire while in storage at Corgenix, Corgenix shall promptly notify BG Medicine in writing of the Lot or Product that expired and the date on which
such expiration occurred, requesting instructions from BG Medicine regarding the disposition of the expired lots. Corgenix shall dispose of such Lots or Products as directed by BG Medicine. 
 (c) Replacement Product. If either Corgenix or BG Medicine determine, pursuant to Section 2.7(a), that a Lot or Product
does not comply with all of the applicable Specifications, then Corgenix shall replace such Lot or Product at no cost or expense to BG Medicine; provided, however, that if a Product has been properly stored by Corgenix expires before shipment, BG
Medicine shall pay the cost of replacing it if BG Medicine informs Corgenix in writing that BG Medicine desires to replace such Lot or Product. Corgenix shall also be responsible to pay for the BGM Critical Components necessary for the replacement
Product or Lot if it is determined that Product failure is due to materials provided by or activities performed by Corgenix. If Product failure is due to failure of Critical Components provided by BG Medicine, BG Medicine shall be responsible to pay
for Critical Components necessary for replacement Product or Lot, unless the failure of the Critical Components is due to the mishandling of such components by Corgenix. In the event that the failure of the Critical Components is due to
Corgenix’ mishandling, then Corgenix shall remain responsible to pay for Critical Components necessary for replacement Product or Lot. 
 (d) Labeling. Corgenix shall clearly label, in accordance with the Specifications, each Product for supply hereunder with a unique Lot number, part number, description of contents and other
identifying information, as applicable. 
 (e) Inspection of Corgenix Facilities. Per a mutually agreed upon
schedule, BG Medicine will perform or cause to be performed a baseline audit of Corgenix’ quality system. Thereafter, BG Medicine shall have the right, at reasonable times during normal business hours and upon request made upon reasonable prior
notice to Corgenix, to inspect Corgenix’ facilities used for manufacturing the Products for BG Medicine, and Corgenix’ batch records, work-in-progress, raw materials, and production records for the Products supplied to BG Medicine under
this Agreement. Corgenix agrees to establish a corrective action plan to correct any nonconformance identified during an audit and to implement any such corrections in a timely manner. Corgenix shall cooperate in good faith with all requests for
inspection or information from the FDA. Further, each Party agrees to notify the other immediately in writing in the event (i) any action is taken or threatened by the FDA relating to the Product; (ii) any inspection of either Party’s
facility is scheduled by FDA; or (iii) any unscheduled inspection by

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
FDA occurs. Each Party agrees to consult with the other regarding any deficiencies raised by any FDA inspection and to cooperate in responding to any adverse regulatory findings in a timely
manner. The Parties agree to take timely action to rectify or obtain rectification of any deficiencies identified during the course of any FDA inspection. 
 (f) Technical Contacts. Within thirty (30) days of the Effective Date, each Party shall notify the other Party in writing of the names, telephone number, fax numbers, and e-mail
addresses of at least one person to serve as the Party’s technical contact under this Agreement and at least one person to serve as the Party’s business contact under this Agreement. A Party may change its business or technical contacts at
any time with written notice to the other Party. 
 2.8 Product Warranties. Corgenix warrants that the Products supplied
by Corgenix hereunder will, through product expiry: (i) conform to the applicable Specifications; and (ii) be free of any manufacturing defects. Corgenix further represents and warrants that title to all Products supplied by Corgenix
hereunder shall pass to BG Medicine or its designee free and clear of all security interests, liens and other encumbrances. 
 2.9 Shipment; Handling Fees. All Products delivered pursuant to the terms of this Agreement shall be suitably packed for shipment by Corgenix in accordance with the applicable Specifications, marked for shipment to the destination
point indicated in the Inventory Release Order for such Product, and shipped FCA, Corgenix’ manufacturing facility (INCOTERMS 2000). Such packing, and the manner of shipment, shall be sufficient to prevent damage, contamination, or degradation
during shipment and during unpacking at the destination. BG Medicine shall pay Corgenix the fees listed in Exhibit D for each drop shipment to a BG Medicine customer. All freight, insurance and other shipping expenses from the point of shipment
shall be borne by BG Medicine or its designee. The carrier shall be selected by BG Medicine or its designee. Corgenix shall use all reasonable commercial efforts to ship quantities of Product for delivery on the dates specified in the applicable
Inventory Release Order. 
 2.10 Inspection and Rejection. 
 (a) Non-Conforming Shipments. If within [***] from receipt of a shipment of Product, BG Medicine or its customer finds that the
Product is visibly damaged, BG Medicine or its customer shall provide Corgenix with a Certificate of Nonconformance for said shipment, such Certificate of Nonconformance to include a written statement specifying the nature and basis for the claim
and a Statement of Non-Compliance for the shipment. BG Medicine or its customer shall also return such non-conforming Product in accordance with Corgenix’ reasonable instructions, at Corgenix’ expense (except as otherwise expressly set
forth under Section 2.7(b)); provided that BG Medicine or its customer may retain a reasonable sample thereof solely for further testing, including for example, testing pursuant to Section 2.10(c). Corgenix shall cooperate to solve such a
claim in good faith as quickly as possible. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (b) Third Party Verification. If, within a period of [***] after
Corgenix’ receipt of a Statement of Non-Compliance, Corgenix is unable to verify that the applicable Product failed to conform to the Specifications at the time of original delivery by Corgenix to the carrier, then the matter shall be submitted
to and be finally decided by a nationally recognized independent testing laboratory if requested by either Party; provided, however, that if Corgenix has, at its sole cost and expense (including the cost of the BGM Critical Components), replaced
such Product with Product acceptable to BG Medicine and its customer, then no such independent laboratory testing under this Section 2.10(b) and 2.10(c) shall be required unless BG Medicine determines, in its sole good faith discretion, that
there is a trend of Products that fail or do not comply with the applicable Specifications. This laboratory shall be selected with mutual agreement by both Parties. Only Products that are not expired as of the date that the defect was identified and
are expected to be utilized within expiration date would be subject to such Third Party Testing as described in the following section. 
 (c) Third Party Testing. BG Medicine or its designee shall send a sample of the non-conforming shipment and a copy of the Certificate of Nonconformance to said testing laboratory within [***] of either Party’s written
request. Said testing laboratory shall be requested by the Parties to complete its testing and to render its written decision, supported by its description of procedures and basis for its findings within [***] after being engaged to perform said
testing. Each Party, at its own expense, shall reasonably assist and cooperate with such laboratory in performing such testing by making available such documentation, facilities, reagents and other materials as the laboratory may request of the
Party. The Parties agree that the written decision of said testing laboratory shall be accepted as final and binding. In case the laboratory test proves that the relevant Product did not comply with the Specifications through expiry, then all cost
and expense of transportation, shipping, insurance, and the like related to the testing shall be paid by Corgenix. 
 (d)
Credit or Refund. In the event that Product supplied by Corgenix under the terms of this Agreement is determined to be non-conforming Product, Corgenix shall reimburse BG Medicine for the full purchase paid to Corgenix, if any, for such
non-conforming Product. Such reimbursement shall also include the cost of the BGM Critical Components included in such non-conforming Product, if it is determined that Product failure is due to materials provided by or activities performed by
Corgenix. If Product failure is due to failure of Critical Components provided by BG Medicine, BG Medicine shall be responsible to pay for Critical Components necessary for replacement Product or Lot. 
 2.11 Product Support. 
 (a) Customer Support and Product Complaint Handling. If requested by BG Medicine, Corgenix shall provide first-call direct customer support and product complaint handling for all Products
under this Agreement, as set forth in this Section 2.11. Compensation to Corgenix for such services shall be agreed to by the parties at the time such request for services are made. Corgenix shall provide a dedicated telephone number for such
calls concerning the Products that is toll-free for callers in the United States, and a voice mail system to record messages received during times when Corgenix is not obligated, as set forth in Section 2.11(b), to staff such telephone line. BG
Medicine shall pay the initial set-up charges for such

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
telephone line and will pay Corgenix for Support Services as per Exhibit D. BG Medicine shall designate the name of such telephone line and the script that Corgenix personnel shall use when
receiving customer calls. If any such calls contain information or questions outside Corgenix’ expertise, Corgenix shall promptly transfer such calls to BG Medicine. Corgenix shall provide support for each customer complaint until Corgenix
closes out each such complaint or, if such complaint is outside Corgenix’ expertise, until Corgenix transfers such complaint in writing to BG Medicine 
 (b) Schedule. If BG Medicine chooses to utilize Corgenix global distribution network, consisting of direct representatives in the US and Distributors outside the US, Corgenix shall dedicate
sufficient personnel to provide the support set forth in Section 2.11(a) and to answer customer calls from 7:30 am MST to 5:00 pm MST, Monday through Friday, excluding federal holidays and excluding up to ten (10) additional days during
the Christmas and New Years Holiday period. Voicemail and fax messages are monitored during this holiday period and shipping is limited to one to two days per week to accommodate the holidays. For messages received during weekends, federal holidays,
and the year-end holiday schedule, Corgenix shall contact each such customer as soon as possible on the next day that Corgenix provides real-time support, but in no event more than two (2) business days after Corgenix resumes such real-time
support. Corgenix’ compensation for such services shall be agreed to by the parties at the time that the request for services is made. 
 (c) Reports. Corgenix shall track each call it receives from any and all customers of Products and shall keep written records of such calls, which shall include, without limitation, the
identity, location and contact information of the customer, the identity of the Product at issue, the date and time of the call, a detailed description of any and all questions, comments or information provided to Corgenix by such customer, any and
all information or responses provided by Corgenix to such customer, and whether or not Corgenix has closed-out such complaint (the “Call Tracking Report”). The Parties shall work together in good faith to agree on a protocol for
such Call Tracking Report within sixty (60) days after the Effective Date. Corgenix shall provide BG Medicine a copy of the Call Tracking Report at least once each week for the first three (3) months after the Effective Date, and on the
first business day of every month thereafter, or more frequently upon BG Medicine’s reasonable request. Notwithstanding the foregoing, for any and all calls from any Third Party that reports a complaint about any Product, Corgenix shall, within
twenty-four (24) hours of receiving such call, notify BG Medicine in writing of such complaint, which notice shall include, without limitation, the identity of the customer and Product, the nature of the complaint, and a description of any and
all corrective actions that Corgenix has taken or intends to take (each, a “Complaint Report”). The Complaint Report shall include, as applicable, an initial assessment of Medical Device Reporting (“MDR”) status (as
required by the U.S. Food and Drug Administration (FDA) Regulation 21 CFR Part 803) or need for Vigilance reporting (“Vigilance”) as required by the European Union In Vitro Diagnostic Directive (“IVDD”) or the Canadian Medical
Device Regulations (“CMDR”). BG Medicine will be responsible for filing reports under any MDR or Vigilance reporting obligation. Corgenix shall provide BG Medicine a summary written report every three (3) months of all such Complaint
Reports issued during the previous three (3) month period. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (d) Order Processing. Corgenix shall provide order processing for all Products
under this Agreement, as set forth in this Section 2.11. Compensation to Corgenix shall be as specified in Exhibit D. 
 (e) Warehousing. Corgenix shall provide warehousing and inventory handling for all Products under this Agreement, as set forth in this Section 2.11. All Products shall be stored in conditions specified in the Product
Specifications. Corgenix will be responsible to establish and maintain appropriate storage conditions and procedural controls according to Good Manufacturing Practices (GMP). Compensation to Corgenix shall be as specified in Exhibit D. 

2.12 Invoicing. Corgenix shall submit invoices for Products to BG Medicine as follows: (i) for Products manufactured from the
Pilot Lots, no earlier than the date that BG Medicine accepts such Pilot Lots and the validation pursuant to Section 2.7(a); (ii) for Products after the Pilot Lots, no earlier than the date that BG Medicine provides Corgenix with written
authorization under Section 2.7(a) that such Products may be provided to Third Parties; and (iii) for shipping and handling charges pursuant to Section 2.9 and Exhibit D, no earlier than the first day of the month following the month
in which the shipping and handling charges were incurred. Corgenix shall send all invoices to BG Medicine’s address for notices hereunder or such other address as designated by BG Medicine in writing and each such invoice shall state the
aggregate and applicable unit Transfer Prices, pursuant to Section 4.2, for the Products invoiced. The invoice for (iii) above shall be submitted as a single invoice for all shipments which occurred the prior month, and shall separately
itemize any insurance, taxes, handling fees or other costs incident to the transfer(s) or shipment(s) initially paid by Corgenix but to be borne by BG Medicine pursuant to this Agreement. 
 2.13 Transfer of Title. BG Medicine hereby acknowledges that upon acceptance by BG Medicine of Pilot Lot or Lot pursuant to
Section 2.7(a) and submission of invoices by Corgenix to BG Medicine pursuant to Section 2.12, transfer of title of the Pilot Lot or Lot from Corgenix to BG Medicine shall have occurred. 
 ARTICLE 3 
 CAPITAL EQUIPMENT 
 3.1 Lyophilizer. BG Medicine shall purchase the lyophilizer and related cooling
tower as described in Exhibit K. In connection with this capital purchase, BG Medicine agrees to spend up to $[***] for the purchase and installation of such instrument and cooling tower at Corgenix’ facility. BG Medicine shall reimburse up to
$[***] of documented expenditures incurred by Corgenix for any other facility modification costs necessary to support and operate the lyophilizer. Corgenix shall be responsible for: a) the validation of the instrument in accordance with applicable
regulations, b) the development of methods to produce lyophilized components required for the Product(s) to be produced under this Agreement, and d) ongoing maintenance, insurance and operating expenses related to this instrument. BG Medicine will
maintain ownership of the instrument and will have the right to file necessary security documents to register its ownership interests in the instrument under applicable laws. Corgenix agrees and

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
represents that it will not encumber this instrument in any manner and will allow BG Medicine to remove the instrument from its premises at any time. Corgenix also agrees to sign any necessary
documentation or filings evidencing BG Medicine’s unencumbered ownership interest in the instrument. In addition, Corgenix agrees that it will maintain the instrument on an ongoing preventative maintenance agreement with SP Industries and will
keep the instrument in good repair and operating condition at all times. Failure to maintain insurance or a maintenance agreement on the instrument will be considered a material breech of this Agreement. In addition, failure to maintain insurance
and an active maintenance agreement on the lyophilizer will terminate Corgenix’ right to utilize the instrument for its own production requirements as set forth below. Corgenix is required under this provision to provide BG Medicine evidence of
insurance and in force maintenance agreement. BG Medicine reserves the right to finance the purchase of this instrument at the time of purchase or use this instrument as collateral in connection with a financing agreement at any time in the future.
In connection with this right, Corgenix agrees to execute the corresponding agreements and undertake the necessary actions to allow BG Medicine to utilize this instrument as collateral in connection with a BG Medicine financing facility. 

3.2 Lyophilizer Capacity. BG Medicine shall have first priority on utilization of lyophilizer capacity for the production of any
product requirements that it may have. Any BG Medicine production requirements will advance to the front of any schedule queue for production of lyophilized components and will take priority over any other Corgenix production requirements.

 3.3 Use for Corgenix Production Requirements. Subject to the provisions of Section 3.1, Corgenix shall be allowed
to use the lyophilizer for its own production requirements at a cost to be mutually agreed upon in the future prior to Corgenix’ use, subject to: a) receiving advance written authorization from BG Medicine for each product/component that
Corgenix intends to use the instrument for, and b) establishment of proper cleaning procedures. Corgenix agrees that it will not use the instrument to process any material that contains organic compounds, acids, bases or other materials that will be
harmful to the instrument or will otherwise contaminate the instrument and make unsuitable for use in manufacturing Products under this Agreement. 
 ARTICLE 4 
 PAYMENTS 
 4.1 Start-Up Payments. Upon the Effective Date of Agreement, BG Medicine shall pay Corgenix the following amounts, as set forth in
this Article 4: 
 (a) An upfront payment of [***] Dollars ($[***]), in consideration for Corgenix’ obligations
under Section 2.2(a). Actual charges are billed on a time and materials basis according to activities and services specified in the attached Exhibits subject to the limitations set forth in Section 2.2(a). 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 4.2 Transfer Prices. 
 (a) Pilot Lots. For Products manufactured from the first three (3) Lots produced by Corgenix for BG Medicine’s
validation purposes (the “Pilot Lots”), BG Medicine shall pay Corgenix the prices listed in Exhibit D. BG Medicine shall have the right to use such Products manufactured from the Pilot Lots for any purpose permitted by law and
governmental regulation. 
 (b) Production Lots. Subject to Section 4.2(a), for all Products ordered by
Purchase Orders that are received by Corgenix for Production Lots, BG Medicine shall pay to Corgenix the Transfer Price for each such Product supplied by Corgenix under this Agreement, as set forth in Exhibit D. 
 4.3 Payments for Products. BG Medicine shall make full payment to Corgenix for all Products, including Transfer Prices under
Section 4.2 and handling fees or other costs to be paid by BG Medicine under Section 2.9, within [***] after BG Medicine receives an undisputed invoice from Corgenix pursuant to Section 2.12. 
 4.4 Mode of Payment. All payments shall be made by check or direct wire transfer of United States Dollars in immediately available
funds in the requisite amount to such bank account as Corgenix may from time to time designate by written notice to BG Medicine. 
 4.5 Late Payment. In the event that BG Medicine fails to make any payment when such payment is due hereunder, the amount of such payment shall bear interest at the annual rate equal to the prime rate, as published in the Wall
Street Journal as of the date due plus one percent (1%) with a minimum floor of eight percent (8%) calculated from the date due until the date paid provided that the payment of such interest shall not be deemed an alternate for the
sums owing on the due dates which payments shall be deemed to be in default and remain subject to the termination provisions herein. This Section 4.5 shall in no way limit any other remedies available to either Party. 
 ARTICLE 5 
 LICENSES 
 5.1 Grant to Corgenix. BG Medicine hereby grants Corgenix a non-exclusive worldwide license,
without the right to sublicense, under the BG Medicine Technology, to use the Critical Components solely in the manufacture of Products under this Agreement during the Term. Such license will expire with the termination of this Agreement.

 5.2 Grant to BG Medicine. Corgenix hereby grants BG Medicine a non-exclusive, worldwide, perpetual license, without
the right to sublicense, under the Corgenix Technology, to make, have made, use, sell and offer for sale Products and any and all improved or modified versions of such Products. For any and all proposed agreements between BG Medicine and a Third
Party whereby such Third Party shall have access to Corgenix Technology, BG Medicine shall notify Corgenix of BG Medicine’s intent to negotiate such proposed agreement(s) in sufficient time to discuss any concerns that Corgenix may have, but in
no event later than ten (10) days after the signing of, or verbal agreement to, a non-binding term sheet with such Third

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Party. If Corgenix expresses to BG Medicine in a timely manner Corgenix’ concerns about such proposed agreement(s), then BG Medicine shall, in good faith, consider such concerns in its
further negotiations with such Third Party. BG Medicine solely owns all BG Medicine Technology including any improvements during the course of its relationship with Corgenix. 
 5.3 Technology Transfer. Each Party shall, in good faith, promptly and completely transfer the Corgenix Know-How or BG Medicine
Know-How, as applicable, to the other Party to enable such other Party to exercise its rights and fulfill its obligations under this Agreement. 
 5.4 No Other Rights. Except for the rights expressly granted under this Agreement, no right, title or interest of any nature whatsoever is granted by either Party to the other Party. 
 ARTICLE 6 
 CONFIDENTIALITY 
 6.1 Confidentiality Obligations. Each Party agrees that, for the term of this
Agreement and for five (5) years thereafter, such Party will keep, and will ensure that its officers, directors, employees and agents keep, strictly confidential and will not publish or otherwise disclose and will not use for any purpose except
as permitted hereunder any Confidential Information furnished to it by the other Party pursuant to this Agreement (including, without limitation, know-how of the disclosing Party); provided that, if any such Confidential Information is disclosed
orally, the disclosing Party shall provide the receiving Party a written summary of such Confidential Information within thirty (30) days after such initial oral disclosure. The foregoing confidentiality obligations will not apply to any
information to the extent that it can be established by such receiving Party that such information: 
 (a) was already
known to the receiving Party as evidenced by its written records, other than under an obligation of confidentiality, at the time of disclosure; 
 (b) was generally available to the public or was otherwise part of the public domain at the time of its disclosure to the receiving Party; 
 (c) became generally available to the public or otherwise becomes part of the public domain after its disclosure and other than
through any act or omission of the receiving Party in breach of this Agreement; 
 (d) was subsequently lawfully
disclosed to the receiving Party by a Third Party other than in contravention of a confidentiality obligation of such Third Party to the disclosing Party; or 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (e) was developed or discovered by employees of the receiving Party or its affiliates
who had no access to the Confidential Information of the disclosing Party, all as evidenced by the receiving Party’s written records. 
 6.2 Permitted Disclosures. Each Party may disclose the other’s Confidential Information to the extent such disclosure is reasonably necessary in filing or prosecuting patent applications,
prosecuting or defending litigation, advising investors and the investment community of the results of the activities hereunder (subject to the prior written consent of the other Party, which consent will not be unreasonably withheld or delayed),
complying with applicable governmental regulations, or otherwise in performing its obligations or exercising its rights hereunder. If a Party is required to make any such disclosure of the other Party’s Confidential Information, it will give
reasonable advance notice, as soon as possible, but at least with two weeks notice, to that other Party of such disclosure requirement, will cooperate with the other Party in its efforts to secure confidential treatment of such Confidential
Information prior to its disclosure, and, save to the extent inappropriate in the case of patent applications, will use all reasonable efforts to secure confidential treatment of such information prior to its disclosure (whether through protective
orders or confidentiality agreements or otherwise). 
 6.3 Disclosure of Agreement Terms. Except to the extent required
by law or as otherwise permitted in accordance with this Section 6.3, neither Party shall make any public announcements concerning this Agreement or publish the terms hereof without the prior written consent of the other Party. Notwithstanding
the foregoing, either Party shall have the right to disclose this Agreement or the terms hereof to the extent disclosure is required under applicable law, regulation or valid order of a court or other governmental body to which such Party is
subject, provided that such Party shall in good faith seek to minimize the extent of such disclosure through a protective order or confidential treatment order and, provided further, that such Party shall, as soon as practicable after becoming aware
of the need for such disclosure, give written notice to the other Party of the need for such disclosure so that such other Party may (if it elects and at its own cost) also seek a protective order or other confidential treatment. 
 6.4 Publicity. The Parties shall coordinate all activities related to public disclosure regarding this Agreement. Neither Party shall
make any public disclosure regarding this Agreement without the prior written consent of the other Party, which shall not be reasonably withheld. 
 ARTICLE 7 
 REPRESENTATIONS AND WARRANTIES 
 7.1 Representations by Corgenix. Corgenix represents and warrants that as of the Effective Date: (i) it is duly organized and
validly existing under the laws of the jurisdiction of its incorporation and has full corporate power and authority to enter into this Agreement; (ii) it has taken all corporate actions necessary to authorize the execution and delivery of this
Agreement and the performance of its obligations under this Agreement; and (iii) the performance of its obligations under this Agreement do not conflict with, or constitute a default under its charter documents, any contractual obligation of
Corgenix or any court or administrative order. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 7.2 Representations by BG Medicine. BG Medicine represents and warrants that, as of
the Effective Date: (i) it is duly organized and validly existing under the laws of the jurisdiction of its incorporation and has full corporate power and authority to enter into this Agreement; (ii) it has taken all corporate actions
necessary to authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement; and (iii) the performance of its obligations under this Agreement do not conflict with, or constitute a default
under its charter documents, any contractual obligation of BG Medicine or any court order. 
 7.3 Disclaimer of
Warranties. EXCEPT AS SPECIFICALLY SET FORTH IN THIS ARTICLE 7 OR SECTION 2.8, NO PARTY MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE,
NON-INFRINGEMENT, AND ANY OTHER STATUTORY WARRANTY. 
 ARTICLE 8 
 INDEMNITY 
 8.1 Indemnity by BG Medicine. BG
Medicine hereby agrees to defend, indemnify and hold Corgenix, its employees, agents and Affiliates harmless against any and all Third Party claims, liabilities, losses, damages or expenses, (including, without limitation, attorneys fees), to the
extent resulting from, arising out of, or connected with any inaccuracy, breach of, or nonfulfillment of any covenant, representation, warranty or agreement made by or any other obligation of BG Medicine contained in this Agreement. Notwithstanding
the foregoing, Corgenix, its employees, agents and Affiliates shall not be entitled to indemnification for any claim, liability, loss, cost, damage or expense to the extent caused by its or their own fraud, misrepresentation, negligence or
malfeasance. 
 8.2 Indemnity by Corgenix. Corgenix hereby agrees to defend, indemnify and hold BG Medicine, its
employees, agents and Affiliates harmless against any and all Third Party claims, liabilities, losses, damages or expenses, (including, without limitation, attorneys fees), to the extent resulting from, arising out of, or connected with:
(i) any inaccuracy, breach of, or nonfulfillment of any covenant, representation, warranty or agreement made by or other obligation of Corgenix contained in this Agreement, or (ii) any products liability or negligence claim arising from
the Products produced under this Agreement. BG Medicine, its employees, agents and Affiliates shall not be entitled to indemnification for any claim, liability, loss, cost, damage or expense to the extent caused by its or their own fraud,
misrepresentation, negligence or malfeasance. 
 8.3 Defense; Settlement. The indemnified party shall give the
indemnifying party reasonably prompt notice of any claims of Third Parties as to which it proposes to demand indemnification hereunder. The indemnifying party shall have the right to assume the good faith defense, compromise or settlement of any
such claim (without prejudice to the right of the

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
indemnified party to participate in such defense) at its own expense through attorneys reasonably acceptable to the indemnified party, but may not, without the prior written consent of the
indemnified party agree to (i) any injunctive relief or restrictions affecting the indemnified party, or (ii) any settlement which would adversely affect the business or operations of the indemnified party, including, without limitation,
any admission of wrongdoing or fault by the indemnified party. If the indemnifying party does not elect to defend such claim or suit within ten (10) days after having received written notice thereof or fails to prosecute its defense diligently,
the indemnified party may at its sole discretion defend against such claim or suit at the indemnifying party’s expense. The indemnified party may thereafter elect to settle such claim or suit or otherwise enter into a compromise with the
claimant. 
 8.4 Damages; Costs. If damages and/or costs are awarded against the indemnified party in any such claim or
suit, whether or not Corgenix and/or BG Medicine conduct the defense of such claim or suit, the indemnifying party shall indemnify and hold harmless the indemnified party for all such damages and/or costs. All other costs and/or fees which result
from the assertion of any such claim or suit, including but not limited to attorneys’ fees, incurred by the indemnified party in defense of any such claim or suit shall be reimbursed to the indemnified party by the indemnifying party.

 ARTICLE 9 
 TERM AND TERMINATION 
 9.1 Term. This Agreement will commence upon
execution by both parties and shall remain in effect through the period ending on the date one year after the Effective Date (the “Initial Term”), and shall automatically renew for subsequent one-year periods thereafter (each, a
“Renewal Term”), unless either Party gives written notice of its intention not to renew no later than one hundred eighty (180) days before the end of the Initial Term or Renewal Term then in effect. In the event of an
assignment under section 10.2, BG Medicine reserves the right to terminate the Agreement at its sole discretion. 
 9.2
Termination for Cause. Either party shall have the right to terminate this Agreement if the other party has materially breached the Agreement; provided, however, that such terminating party shall notify the breaching party in writing of such
breach and, if such breach remains uncured thirty (30) days after the date such notice was sent, the breaching party shall have a right to terminate the Agreement immediately by sending a written termination notice to the breaching party.

 9.3 Termination for Convenience. BG Medicine may terminate this agreement for any reason upon ninety (90) days
written notice, subject to compensating Corgenix for any costs incurred on behalf of BG Medicine through the date of termination. 
 9.4 Consequences of Termination or Expiration. 
 (a) Return of Materials. Upon termination or
expiration of this Agreement each Party will promptly return all records and materials in its possession or control containing or comprising the other Party’s know-how or other Confidential Information to which the former Party does not
expressly retain rights hereunder or under the License Agreement. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (b) Accrued Liability. Termination or expiration of this Agreement for any
reason shall not release either Party hereto from any liability which at the time of such termination or expiration has already accrued to the other Party prior to such time. Such termination or expiration will not relieve a Party from accrued
payment obligations or from obligations which are expressly indicated in this Agreement to survive termination or expiration of this Agreement. 
 (c) Survival. The following Articles and Sections of this Agreement shall survive its termination or expiration: Articles 1, 3, 4, 5 (as set forth therein), 6, 7, 8, 9 and 10 and Sections
2.8, 2.10 and 4.2. 
 ARTICLE 10 
 GENERAL PROVISIONS 
 10.1 Relationship of the Parties. The Parties
are independent contractors. Nothing in this Agreement is intended or will be deemed to constitute a partnership, agency or employer-employee relationship between the Parties. Neither Party will incur any debts or make any commitments for the other
Party. 
 10.2 Assignments. Except as expressly provided herein, neither this Agreement nor any interest hereunder will
be assignable, nor any other obligation delegable, by a Party without the prior written consent of the other Party; provided, however, that a Party shall have the right to assign and otherwise transfer this Agreement as a whole without consent to
any successor that acquires all or substantially all of the business or assets of such Party by way of merger, consolidation, other business reorganization, or the sale of stock or assets, provided that the assigning Party notifies the other Party
in writing of such assignment, and such successor agrees in writing to be bound by the terms and conditions of this Agreement. This Agreement shall be binding upon successors and permitted assigns of the Parties. Any assignment not in accordance
with this Section 9.2 will be null and void. 
 10.3 Force Majeure. Except with respect to payment of money, no
Party shall be liable to the other for failure or delay in the performance of any of its obligations under this Agreement for the time and to the extent such failure or delay is caused by earthquake, riot, civil commotion, war, terrorist acts,
strike, flood, or governmental acts or restriction, or other cause that is beyond the reasonable control of the respective Party. The excused Party shall be excused for a time period reasonably sufficient to remedy the effects of such an event. The
Party affected by such force majeure will provide the other Party with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities), and will
use commercially reasonable efforts to overcome the difficulties created thereby and to resume performance of its obligations as soon as practicable. If the performance of any such obligation under this Agreement is delayed owing to such a force

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
majeure for any continuous period of more than one hundred eighty (180) days, the Parties hereto will consult with respect to an equitable solution, including the possibility of the mutual
termination of this Agreement. 
 10.4 Entire Agreement of the Parties; Amendments. This Agreement constitutes and
contains the entire understanding and agreement of the Parties respecting the subject matter hereof and cancels and supersedes any and all prior and contemporaneous negotiations, correspondence, understandings and agreements between the Parties,
whether oral or written, regarding such subject matter. No waiver, modification or amendment of any provision of this Agreement will be valid or effective unless made in writing and signed by the Parties. 
 10.5 Captions. The captions to this Agreement are for convenience only, and are to be of no force or effect in construing or
interpreting any of the provisions of this Agreement. 
 10.6 Governing Law; Dispute Resolution. This Agreement will be
governed by and interpreted in accordance with the laws of the State of Delaware, applicable to contracts entered into and to be performed wholly within the State of Delaware, excluding conflict of laws principles. 
 10.7 Notices and Deliveries. Any notice, request, delivery, approval or consent required or permitted to be given under this
Agreement will be in writing and will be deemed to have been sufficiently given if delivered in person, transmitted by telecopier (receipt verified) or by express courier service (signature required) or five (5) days after it was sent by
registered letter, return receipt requested (or its equivalent), provided that no postal strike or other disruption is then in effect or comes into effect within two (2) days after such mailing, to the Party to which it is directed at its
address or facsimile number shown below or such other address or facsimile number as such Party will have last given by notice to the other Party. 
 If to Corgenix, addressed to: 
 Corgenix, Inc. 
 11575 Main Street, Suite 400 
 Broomfield, Colorado 80020 
 Attn.: President/CEO 
 Fax: (303) 457-4519 
 If to BG Medicine, addressed to: 
 BG Medicine, Inc. 

610 N. Lincoln Street 
 Waltham, MA 02451 
 Attn.: President/CEO 
 Fax: (781) 895-1119 
 10.8 No Consequential Damages. EXCEPT WITH RESPECT TO UNAUTHORIZED EXPLOITATION OF THE OTHER PARTY’S INTELLECTUAL PROPERTY RIGHTS, BREACH OF CONFIDENTIALITY OR THE INDEMNITY

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
OBLIGATIONS UNDER ARTICLE 7, IN NO EVENT WILL ANY PARTY OR ANY OF ITS RESPECTIVE AFFILIATES BE LIABLE TO THE ANY OTHER PARTY OR ANY OF ITS AFFILIATES FOR SPECIAL, INDIRECT, CONSEQUENTIAL,
INCIDENTAL, EXEMPLARY, OR PUNITIVE DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO, LOSS OF PROFITS OR REVENUE OR CLAIMS OF CUSTOMERS OF ANY OF THEM OR OTHER THIRD PARTIES FOR
SUCH DAMAGES. 
 10.9 Waiver. A waiver by any Party of any of the terms and conditions of this Agreement in any instance
will not be deemed or construed to be a waiver of such term or condition for the future, or of any subsequent breach hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement will be cumulative and none of
them will be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party. 
 10.10
Severability. When possible, each provision of this Agreement will be interpreted in such manner as to be effective, valid, and enforceable under applicable law. The Parties will make a good faith effort to replace the applicable provision with
a valid one, which the Parties agree has effect that is consistent with the original provision. 
 10.11 Compliance with
Laws. Notwithstanding anything to the contrary contained herein, all rights and obligations of BG Medicine and Corgenix are subject to prior compliance with, and each Party shall comply with, all United States and foreign export and import laws,
regulations, and orders, and such other United States and foreign laws, regulations, and orders as may be applicable, including obtaining all necessary approvals required by the applicable agencies of the governments of the United States and foreign
jurisdictions. 
 10.12 Counterparts. This Agreement may be executed simultaneously in any number of counterparts, any
one of which need not contain the signature of more than one Party but all such counterparts taken together will constitute one and the same agreement. 
 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized officers as of the Effective Date, each copy of which will for all purposes be deemed
to be an original. 
  

									
	BG MEDICINE, INC.	    		    	CORGENIX INC.
					
	 By:
	 	 /s/ Pieter Muntendam
	    		    	By:	  	 /s/ Ann Steinbarger

	 Name:
	 	Pieter Muntendam	    		    	Name:	  	Ann Steinbarger
	 Title:
	 	President and CEO	    		    	Title:	  	Senior VP, Sales & Marketing
	 Date:
	 	March 23, 2009	    		    	Date:	  	March 20, 2009

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT A 
 PRODUCTS 
 1. ELISA Reagents and Materials List for
Galectin-3 Production at Corgenix (subject to modification in accordance with mutually agreed to final product specifications) 
  

					
	 Reagents & Materials
	  	Future’s Vendor	 	Catalog No.
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]
			
	 [***]
	  	[***]	 	[***]

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 2. Kit Configuration 
  

					
	 Component
	  	 Quantity
	  	 Packaging

	 Assay Diluent (AD)
	  	45 mL	  	1 bottle
	 TMB Substrate (TS)
	  	15 mL	  	1 bottle
	 Stop Solution (ST)
	  	10 mL	  	1 bottle
	 Wash Concentrate (WC)
	  	100 mL	  	2 bottles
	 Tracer Concentrate (TC)
	  	0.4 mL	  	1 vial
	 Ready-to-use Plate (P)
	  	1 plate	  	1 bag
	 Adhesive plate coversheets
	  	2 sheets	  	2 sheets
	 Low Control (C1)
	  	2 vials	  	2 vials
	 High Control (C2)
	  	2 vials	  	2 vials
	 Standard S1 (S1)
	  	2 vials	  	2 vials

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT B 
 Certificate of Analysis and Specifications 
 Galectin-3 Immunoassay Example-will customize for BGM based on final product specifications 
 BG MEDICINE 
 610N Lincoln Street 
 Waltham, Massachusetts 02451 
  

					
	 CERTIFICATE OF ANALYSIS
  

	 PRODUCT: Galectin-3 96 Test Kit
 KIT LOT NUMBER: XXXXXX
	 	 CATALOG NUMBER:
 EXPIRATION DATE:
	 	 XXXXX
 XXXX

  

					
	 Component
	  	 Lot #
	  	 Expiration Date

	 Standard
	  		  	
	 Low Control
	  		  	
	 Medium Control
	  		  	
	 High Control
	  		  	
	 Tracer Concentrate
	  		  	
	 Tracer Diluent
	  		  	
	 Assay Diluent
	  		  	
	 TMB Solution
	  		  	
	 Wash Concentrate
	  		  	
	 Microplate
	  		  	
	 Stop Solution
	  		  	

  

							
	 Quality Control Results
	  		  		  	
				
		  	Manufacturing Date                     	  	Test Date                     	  	

 Absorbance 
  

							
	  	  	 Value
	  	 Specification
	  	 Result by Assay

	 High Control
	  	     GPL	  	NA	  	     (OD)
				
	 Low Control
	  	     GPL	  	NA	  	     (OD)
	 Medium Control
	  	      GPL
      GPL
	  	 > 0.700 for kit < 1 mo.
 > 0.400 for kit > 1 mo.
	  	     (OD)
	 Reagent Blank
	  	     GPL	  	< 0.050	  	     (OD)
				
	 Curve R2 Value
	  	—        	  	> 0.850	  	
	
	 • = < 1 month from date of manufacture. Date of manufacture Is 1 year
prior to Kit Expiration Date. 
  
 Control
Response

				
	  	  	 Label Range
	  	 Result by Assay
	  	 Result by Assay

	 Standard
	  	     GPL	  	     GPL	  	     (OD)

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Human sera used to prepare the controls included in this kit have been tested and shown to be nonreactive
for HBsAg and negative for antibodies to HCV and HIV1, 2 by the FDA required tests. However, all human blood derivatives, including patient samples, should be handled as though capable of transmitting disease 
 This is to certify that this product conforms to manufacturer’s specifications. 
  

							
				
	  
 Signature
	  	 	  	  
 Date
	  	 
				
	  
 Title
	  		  		  	

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT C 
 START UP EXPENSES 
 All activities are billed as time and materials.
Hourly rates are listed below. Materials are billed according to actual invoice. Estimated costs for start up are $[***] and include but are not limited to the tasks listed below. A complete estimate including workplan will be agreed upon by the
Parties, before any work commences. A full accounting of time and materials will be forwarded to BG Medicine at the end of each month. 
  

	a.	Manufacturing Transfer. Any travel required by Corgenix for training and technology transfer shall be paid by BG Medicine. (estimate:$ [***])

  

	b.	Document Preparation. Time for creating manufacturing, QC and QA documents will be billed at prevailing rates. (estimate $[***]) 

  

	c.	Packaging and Labeling. Includes design, set up charges and printing costs. (estimate $[***]) 

  

	d.	Transportation Stress Testing. Testing is conducted on finished Product to ensure that, after shipment to customers, a product’s performance characteristics
continue to meet all package insert Quality Control claims. (estimate $[***]) 

  

	e.	Package Integrity Testing. Testing is conducted on finished Product to ensure the packaging meets transportation safety regulations. Labor and shipping materials
costs will be billed for actual charges. (estimate $[***]) 

  

	f.	Stability Testing. Establish sampling plan, initiate documents and perform real time stability testing. Accelerated stability testing, if required would be
billed as time and materials. (estimate $[***]) 

  

	g.	Preservative Effectiveness Testing. This includes sending out to third party to test two (2) components. Assay Diluent and Concentrated Tracer (estimate
$[***]) 

 Hourly Labor Rates 
  

			
	 Personnel
	  	 Hourly Labor Rates

	 Executive Management
	  	$[***]
	 R&D Staff
	  	$[***]
	 Regulatory
	  	$[***]
	 QA
	  	$[***]
	 Technical/QC
	  	$[***]
	 Shipping Clerk
	  	$[***]
	 Manufacturing
	  	$[***]

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT D 
 PAYMENTS 
 TRANSFER PRICES 
  

							
	 Period
	 	 Annual Kit Volume
	 	 Price/Kit to BGM
	 	 Comments

	 Calendar Year 2009
	 	First [***] kits	 	$[***]	 	
		 	Kits [***]	 	$[***]	 	
		 	 Kits starting with
 [***]
	 	$[***]	 	
	 Calendar Year 2010
 and beyond
	 	Initial Kits	 	 Price last charged in
 2009
	 	
		 	 Cumulative kits
 (aggregate 2009/2010
 kit volume) [***] and
 beyond
	 	$[***]	 	
	 Minimum annual
 guarantee
	 	[***] kits	 	$[***]	 	 In the event that BGM
 makes a minimum
 annual commitment of
 [***] kits

	 Annual volume
	 	> [***] kits	 	To be negotiated	 	

 HANDLING/ORDER PROCESSING FEES 
 Handling/order processing fees for order processing, warehousing, Drop-Shipping Product to BG Medicine customers on BG Medicine FedEx or customer account and all packaging materials are set forth below.
In the event that the Blue Ice packaging requirement is eliminated, the parties agree to modify the box fee accordingly. 
  

							
	 Box Description
	 	 Size
	 	 Kits/Box
	 	 Box Fee (includes
 Blue Ice)

	 A
	 	12x10x8	 	1	 	$[***]
	 B
	 	13x10x16	 	2-3	 	$[***]
	 C
	 	22x11x16	 	4-9	 	$[***]
	 D
	 	22x18x20	 	10-24	 	$[***]
	 E
	 	24x24x20	 	25-36	 	$[***]

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT E 
 CRITICAL COMPONENTS 
 Supplied by BG Medicine

  

	1.	[***] 

  

	2.	[***] 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT F 
 CE-MARKING COMPLIANCE TASKS 
 Payment to Corgenix for
CE-Marking Services is estimated to be $[***] based on details provided in the Proposal dated December 15, 2008. 
 Products
will be CE Marked according to Corgenix Standard Operating Procedure “CE Marking Procedure” SOP1026, with modifications to reflect that BG Medicine is responsible for: 
  

	1.	Assisting Corgenix in preparation of the Summary and Detail Technical Files. 

  

	2.	Design Control and for providing Design Control SOPs and documentation. 

  

	3.	Post-market Surveillance. 

  

	4.	Assisting Corgenix with annual technical file review. 

  

	5.	Appointing an, or approving a Corgenix recommended, Authorized Representative. 

  

	6.	Notifying Corgenix of any complaints that suggest that the product may have caused or contributed to a death or serious injury, or any malfunctions that would be likely
to cause or contribute to a death or serious injury, and assisting Corgenix in reporting the adverse event. 

 The Corgenix SOP
describes the process for creating and maintaining technical documentation to be in compliance with the European Union In Vitro Diagnostic Directive (IVDD), which controls CE Marking of medical devices. 
 Summary Technical File 
 BG Medicine and
Corgenix will create the Summary Technical File. Copies will be located at Corgenix and BG Medicine, as well as with any OEM partners and the European Authorized Representative. The Summary Technical File must be made available to a requesting
European Competent Authority within two (2) business days. 
 1. The Summary Technical File will contain the following sections:

  

	 	a.	Product Description 

  

	 	b.	Description of Manufacturing Process 

  

	 	c.	Description of IVDD Classification with Justification 

  

	 	d.	Company Overview 

  

	 	e.	Quality Systems Certification 

  

	 	f.	Authorized Representative Information 

  

	 	g.	Detail Technical File — Essential Requirements Dossier 

  

	 	h.	Product Specific Risk Analysis 

  

	 	i.	Package Insert 

  

	 	j.	Kit Box Label 

  

	 	k.	Label Set 

  

	 	1.	Product Specification 

  

	 	m.	FDA Clearance Letter(s) 

  

	 	n.	Performance Characteristics/Validation 

  

	 	o.	CE Declaration of Conformity 

 2. Design Control
SOP’s and documentation 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT F (CONT’D) 
 CE-MARKING COMPLIANCE TASKS 
 3. Post Market Surveillance

 4. Annual Technical File review 
 5. Appointing an Authorized Representative 
 6. Packaging and labeling compliant with the EU IDD; English plus translations to 5 major
languages (Dutch, French, German, Spanish and Italian) 
 7. Adverse Event reporting 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT G 
 PURCHASE ORDER–EXAMPLE–will customize for BG Medicine 

 

 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT H 
 INVENTORY RELEASE ORDER–EXAMPLE–will customize for BG Medicine 

 

 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT I 
 INVENTORY REPORT 
 Form and content of report to be
mutually agreed to by the parties 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

															
	BG Medicine CURRENT INVENTORY SHEET	 	     Inventory Conducted:

	  
 Released Inventory
  

	 Product
	 	 Part #
	 	 Plate Lot
	 	 Kit Lot
	 	 Expire
	 	 Sequest
	 	 In Stock
	 	 Total Kits

 Sequestered 
  

															
	 Customer
	 	 Part #
	 	 Plate Lot
	 	 Kit Lot
	 	 QTY
	 	 Expire
	 	 Project Code
	 	 Comment

 Product on Hold 
  

													
	 Product
	 	 Part #
	 	 Plate Lot
	 	 Kit Lot
	 	 QTY
	 	 Expire
	 	 Reason

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT J 
 STABILITY PLANS TO BE ATTACHED 
 To be mutually agreed
to by the parties 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 TEST METHOD 
  

					
	Title:	 	STABILITY PROGRAM, SAMPLE RECOVERY FOR	  	Document Number: TM5054
	 	 	GALECTIN-3	  	 
	 	 
	Supersedes/Date:
New                CO No.: 09-0371	  	Revision: 00
	 	 
	QA Approval/Date: Dan Simpson 2009-06-11	  	Effective Date: 2009-06-12

 1. INTRODUCTION 
 This document describes
the scheduling and testing of Galectin-3 manufactured product on the stability program that require Stress by Opening monthly (SOM) and Sample Recovery (SR) testing. All stability testing is real time, tested throughout the shelf life of the kit.

 2. RESPONSIBILITY 
 The
Quality Control Department is responsible for the implementation of the stability program; for the proper execution of the storage, kit selection, testing, and reporting required by this document; and for reviewing all testing, data sheets, and
master sheets each time point. 
 Although stability testing is not required post clearance by regulatory bodies when supported by
Transportation Stress Testing (SOP1037), Corgenix will monitor real time stability of products post production. BG Medicine representatives and Corgenix Technical Review Board (SOP1015) shall be responsible for determining when a
significant change has been made to an existing product and initiating notification for QC to put the appropriate three lots into the stability program. Refer to Design Controls for Changes to an Existing Product (SOP5107). BG Medicine
representatives and Corgenix Technical Review Board shall also be responsible for reviewing data and extending expiration dates. 
 3.
REFERENCES 
 Stability Testing of In Vitro Diagnostic Reagents EN 13640: 2002 
 Microplate Readers/Calibration Plate/Reader Software (ES1700) 
 Nonconformance Reports
(SOP1012) 
 Technical Review Board (SOP1015) 
 Transportation Stress Testing (SOP1037) 
 Procedure for Retesting (SOP3004)

 Design Controls for Changes to an Existing Product (SOP5107) 
 Waste Disposal (SOP7002) 
 Stability Program (TM5050) 
 Galectin-3 Test Kit Product Specification (PS043) 
 Appropriate Galectin-3 Test Kit Package Insert 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 TEST METHOD 
  

					
	Title:	 	STABILITY PROGRAM, SAMPLE RECOVERY FOR	  	Document Number: TM5054
	 	 	GALECTIN-3	  	 
	 		 
	 	 		  	Revision: 00
	 		 
	 	 	 	  	Effective Date: 2009-06-12

 4. SAFETY 
 Follow all general laboratory
safety rules. 
 Though the human serum/plasma samples have been tested negative for Hepatitis B surface antigen, Hepatitis C, and HIV
antibodies, treat all reagents and samples as though infectious. 
 Acid solutions used in stopping solutions are irritants and care should be
taken to avoid contact with skin and clothing. 
 5. EQUIPMENT/MATERIALS 
 Kits and components sufficient for testing as outlined 
 Microplate reader (calibrated per
ES1700) 
 6. PROCEDURE 
  

	 	6.1	Stability Testing 

  

	 	6.1.1	A minimum of one lot per year shall be tested for Sample Recovery. For new products or an existing product undergoing significant change, The first three lots of
product must be put into SOM/SR testing. The first three lots represent the first three sequential lots manufactured for commercial sale of a new product or the first three sequential lots manufactured after the significant change is implemented. If
three sequential lots are not used for stability, justification of the use of non-sequential lots must be included in the stability file with BG Medicine approval. A memorandum may be written for justification and signed by Quality Assurance, the
Product Manager, and Quality Control. 

  

	 	6.1.2	Stress by Opening Monthly (SOM)/Sample Recovery (SR) Testing. The schedule below represents the MINIMUM required testing. 

  

					
	  	 	 SOM and SR
	  	 TIME POINTS

		 	The first three lots manufactured and a minimum one lot per year thereafter.	  	Monthly: months 1-15 as applicable by expiration dating. The final test point shall be scheduled at least one day after the kit expiration date to ensure that testing encompasses
the entire shelf life of the product.

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 TEST METHOD 
  

					
	Title:	 	STABILITY PROGRAM, SAMPLE RECOVERY FOR	  	Document Number: TM5054
	 	 	GALECTIN-3	  	 
	 		 
	 	 		  	Revision: 00
	 		 
	 	 	 	  	Effective Date: 2009-06-12

  

	 	6.1.2.1	Seven standard curve points, 2 kit controls, and 6 patient serum samples will be tested in duplicate. All sera may not be sufficient for the full 15 months of testing.
Comparable sera shall be substituted as necessary. 

  

	 	6.2	Acquisition of Materials and Scheduling of Kits 

  

	 	6.2.1	All lot specific components as dispensed during the routine manufacturing process shall be used One extra bottle of standard and of each control will be included with
each kit. Tracer concentrate and wash buffer concentrate will be diluted sufficient for analysis, residual concentrate will be retained for subsequent analysis with a particular kit. 

  

	 	6.2.2	Two kits will be required for each Sample Recovery test point. Additional kits are included if retesting is required. Scheduling is shown below.

  

																																	
	 Month
	  	1	  	2	  	3	  	4	  	5	  	6	  	7	  	8	  	9	  	10	  	11	  	12	  	13	  	14	  	15	 	Retest
		  	A	  	A	  	A	  	B	  	B	  	B	  	C	  	C	  	C	  	D	  	D	  	D	  	E	  	E	  	E	 	 R1, R2,
 R3,
R4

 5 (SS) + 4 (Retest) = 9 Total kits required per isotype 
  

	 	    	Set down numbers: SR-XXX-A, SR-XXX-B, SR-XXX-R1, SR-XXX-R2, where XXX is the kit lot number and the alphanumeric subscript (e.g., –A, –R1) identifies each
specific kit. 

  

	 	6.3	Storage Conditions 

  

	 	    	All kits tested for stability will be stored in a refrigerator at 2-8°C. 

  

	 	6.4	Set Down of a Kit Lot for Stability 

  

	 	    	Refer to Stability Program TM5050 for details to set down a new stability lot number. 

  

	 	6.5	Testing 

  

	 	6.5.1	Run each assay according to its package insert. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 TEST METHOD 
  

					
	Title:	 	STABILITY PROGRAM, SAMPLE RECOVERY FOR	  	Document Number: TM5054
	 	 	GALECTIN-3	  	 
	 	 
	 	  	Revision: 00
	 	 
	 	  	Effective Date: 2009-06-12

  

	 	6.5.2	A fresh kit specific wash will be diluted for each time point. 

  

	 	6.5.3	All dilutions are per package insert or accepted QC practice. 

  

	 	6.5.4	The control sera should be the same as those used during Final Product Testing. 

  

	 	6.5.5	Use a copy of the TM5054-1 worksheet that had been previously prepared. 

  

	 	6.6	Calculations 

  

	 	6.6.1	Enter the ODs into the appropriate Sample Recovery template previously set up in the QC stabilities file. Alternately, if the suggested worksheet was followed in
testing, use the copy/paste function described in ES1700 and transfer the raw OD numbers into the raw data sheet of the spreadsheet. The raw ODs will then be copied into the appropriate places in the spreadsheet(s). If the raw data was
printed automatically when read, there is no need to print the raw data sheet. The program will automatically calculate the mean OD and % CV for each sera. 

  

	 	6.6.2	 For 3rd order polynomial regression, the four coefficients and r2 are generated as follows: 

  

	 	6.6.2.1	Open the PSI-Plot program, a blank spreadsheet will open. 

  

	 	6.6.2.2	In Column C1, enter the mean ODs from the Standard Curve, beginning with the 10 ng/mL Standard. 

  

	 	6.6.2.3	In Column C2, enter the Standard Curve values, beginning with the 10 ng/mL Standard. 

  

	 	6.6.2.4	Under the “Math” menu, select “fitting”, then “polynomial”. Type “3” in the box labeled “Order”. Choose
“OK”. 

  

	 	6.6.2.5	A “Polynomial Fitting Report” will be generated. The assay name may be entered after “Date File Name”. Print the report and choose “OK”.
Next, print the page with the initial data entry (new data will have been added by PSI-Plot). 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 TEST METHOD 
  

					
	Title:	 	STABILITY PROGRAM, SAMPLE RECOVERY FOR	  	Document Number: TM5054
	 	 	GALECTIN-3	  	 
	 	 
	 	  	Revision: 00
	 	 
	 	  	Effective Date: 2009-06-12

  

	 	6.6.2.6	The four coefficients generated are labeled as “a[0], a[1], a[2], a[3]” under “The Order of Polynomial” section. Enter these into the Excel
spreadsheet where indicated. Values will be calculated automatically by Excel. 

  

	 	6.6.2.7	 The r2 coefficient is labeled “COD” under the “Goodness of Fit Statistics” section. Enter the r2 into the Excel spreadsheet where indicated. 

  

	 	6.6.3	Copy the sample recovery values into the next available column to the right of time zero on page 2 of the spreadsheet and labeled with the appropriate time point.

  

	 	6.6.4	Refer to the appropriate Product Specification and determine if each assay meets specification listed. All results shall meet acceptance criteria as specified in the
appropriate Product Specification for all testing time points. . 

  

	 	6.6.5	Sign, date, and attach all documents inside the stability file folder on the left side. Submit to QC or Product Support for review. 

  

	 	6.6.6	When all scheduled testing for a plate lot is complete, attach the tickler file index card to the inside left of the lot’s stability file folder. Remove any
remaining kits from the stability bins and disposition according to Waste Disposal (SOP7002). 

  

	 	6.7	Retesting of Stability Kits 

 Refer to SOP3004 for retesting procedure. If repeated out of specification results are obtained, BG Medicine shall be notified immediately and an investigation completed per SOP3004. 
 7. APPENDICES/ATTACHMENTS 
 Appendix 1: List of Excel Spreadsheet Forms for TM5054 
 Appendix 2: Plate Set Up Diagram SR Testing 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 TEST METHOD 
  

					
	Title:	 	STABILITY PROGRAM, SAMPLE RECOVERY FOR	  	Document Number: TM5054
	 	 	GALECTIN-3	  	 
	 	 
	 	  	Revision: 00
	 	 
	 	  	Effective Date: 2009-06-12

 APPENDIX 1: List of Excel Spreadsheet Forms for TM5054 
 The following forms can be found in Excel under: Current Company 
 Network/Department/Quality Control/Quality Control Templates. 
 Stability Sample Recovery Testing for Galectin-3
(TM5054-1) 
 Stability Master Sheet (TM5054-2) 
 APPENDIX 2: Plate Set Up Diagram for SR Testing 
 RB = reagent blank 
  

					
	 	  	 1 2
	  	 3 4

	 A
	  	10 ng/ml Std	  	Kit Low Control
	 B
	  	5 ng/ml Std	  	Kit High Control
	 C
	  	2.5 ng/ml Std	  	1
	 D
	  	1.25 ng/ml Std	  	2
	 E
	  	0.625 ng/ml Std	  	3
	 F
	  	0.313 ng/ml Std	  	4
	 G
	  	0.156 ng/ml Std	  	5
	 H
	  	RB	  	6

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT K 
 LYOPHILIZER DESCRIPTION 
 Final Quote from SP
Industries to be included as exhibit K in final signed agreement 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit K 
 [Graphic] 
 815 Route 208 
 Gardiner, New York 12525 
 1-800-431-8232 
 1-845-255-5000 
 1-845-255-5338 (Fax) 
  

							
	To:	  	Jeff Moore	  	From:	  	Paul Coiteux
	Fax:	  		  		  	
	Phone:	  	(617) 784-2450 ext	  	Date:	  	Feb-27-2009
	Re:	  	BG-Medicine–Used BM 1000	  		  	

 Thank you for contacting SP Industries, manufacturers of FTS, Hull, VirTis and Hotpack Equipment. 
 We are pleased to provide your quotation as requested. 
 If you have any questions concerning the quotation, or if you would like further information on any of SP Industries’ other products, including Wilmad-LabGlass glassware or Hotpack washers and environmental chambers, please do not
hesitate to contact us directly, or visit our website at Spindustries.com. 
 We thank you again for considering SP Industries products in your
purchasing plans. 
 I look forward to assisting you with your new equipment. 
 Best regards. 
 Paul Coiteux 
 Director Technical Sales and Support 
 800-431-8232 x 2027 
 Paul.Coiteux@spindustries.com 
 [Graphic] 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
		  	Exhibit K	  	
		  	[Graphic]	  	ISO-9001 REGISTERED
		  		  	Please make your order out to SP Industries
	 815 Route 208 Gardiner, NY 12525-9989 800.431.8232 Phone: 845.255.5000 Fax: 845.255-5338
www.virtis.com

  

					
	Quote For:	  	Jeff Moore	  	Payment Terms:
		  	 BG Medicine
 Waltham, MA 02451
 USA
	  	 50% with confirming purchase order, 50% Net 30
 days subject to standard credit review.

			
	Phone:	  	(617) 784-2450	  	
	Fax:	  		  	
	E-mail:	  	JMoore@BG-Medicine.com	  	

  

													
	 Date
	 	 Quote #
	 	 Expires
	 	 Ship ARO
	 	 Ship Via
	 	 Prepared by:
	 	 Phone #:

	 02/27/09
	 	RESQ15378-02	 	60 days	 	See Notes	 	Best Way	 	Rich Gliedman	 	800-431-8232

  

									
	 Qty
	  	 Part #
	    	 Description
	  	 Unit Price
	  	 Ext. Price

	1	  	B1K204	    	 USED BENCHMARK 1000
 Serial
Number: 215661. The unit is being offered on an “as available” basis and comes with a 1 year warranty.
 Includes:
	  	$[***]	  	$[***]
					
		  		    	 >4 usable plus one radiant 16” X24” shelves providing for a shelf area of 10.67 ft2 (.99 m2) and a shelf clearance of
78mm.
 >Refrigeration system is our EL70 system.
 >The shelf stack is capable of a temperature range from
 -70°C to +65°C.
 >The condenser will have a 24 hour capacity of 20 Liters.
	  		  	
		  		    	 >The condenser blank off temperature is -85°C.
 >Vacuum will be provided by 2 redundant Leybold vacuum pumps.
 >The shelf stack, condenser
and product chambers will be constructed of 316L stainless-steel.
 >Hydraulic stoppering
 >8” Isolation Valve
 >Maestro Control
System with:
 •    Pirani and Capacitance Manometer Vacuum Gauges

•    Barometric Endpoint software for dryness testing
 •    12 product probes
	  		  	
					
		  		    	 >Shipping and insurance
 >1 Preventitive Maintenance Visit
	  		  	
					
	1	  		    	Delta 10 Evaporative Cooling Tower. The tower will be ordered with a heated sump so that it will be cold weather compatible	  	$[***]	  	$[***]
					
	1	  	ISA	    	 Installation and Start-up Assistance- (price is per week) (Limited to 45 hours; additional hours $220/hour)
 -Assist the maintenance department or the operator with proper installation of the unit.
 -Check unit for proper utility support, power, water, etc...
 -Explain in detail the operation
and service requirements of all sub-systems. Training to include routine maintenance as well as long term maintenance.
	  	$[***]	  	$[***]

 [Graphic] 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit K 
  

									
	 Qty
	  	 Part #
	    	 Description
	  	 Unit Price
	  	 Ext. Price

		  		    	 -Review in detail spare parts lists outlining recommended spares both short and long term.
 -Review print support documentation including main system, electrical and refrigeration drawing.
 - Provide complete operation and support training on all provided control systems.
 Customer must
have the following ready prior to service arrival:
 1. Unit must be in its final location.
 2. The electrical service must be connected and operational.
 3. Water supply for the compressor system must be connected and operational.
 4. Product and condenser drains must be connected to
drainage system and be operational.
 5. Any shipping damage should be disclosed.
	  		  	
					
		  		    	Notes:	  		  	
					
		  		    	 1) Receipt of 50% deposit required by March 15, 2009.
 2) Cooling tower is not cancelable and will be order from Delta upon receipt of BG purchase order.
 3) Unit will be shipped within 1 week of receipt of initial deposit.
 4) Shipment is estimated to be one
week.
	  		  	
			
	 Please make out Purchase Orders to SP Industries /
New York Equipment Group for all
HotPack, VirTis,
and FTS products.
	  	 Sub Total
 FOB FACTORY
	  	 $[***]
 $[***]

		  		    		  	 	  	 
		  		  	Total	  	$[***]

 Please reference quote # when placing
order. Confirmation of order should be sent by formal purchase order. Please make your order out to SP Industries. Delivery time is estimated and is subject to prior sale and/or plant loading. Shipments are made F.O.B. manufacturing plant. Any
freight or trading charges will be prepaid and added. Credit terms subject to prior approval. SP Industries equipment carries a one-year warranty on parts and labor and two year refrigeration warranty. Prices subject to change–prices based upon
total purchase–all delivery, training or consulting services to be billed at published rates for each activity involved–generally all hardware computer components proposed above are covered by a limited one year warranty, covering parts
and labor on a depot basis–we specifically disclaim any and all warranties, express or implied, including but not limited to any implied warranties or with regard to any licensed products. We shall not be liable for any loss of profits,
business, goodwill, data, interruption of business, nor for incidental or consequential merchantability or fitness of purpose, damages related to this agreement. Minimum 20% restocking fee with original packaging. SP Industries is a Equal
Opportunity Affirmative Action employer. 
  

			
	AUTHORIZED SIGNATURE:	 	  

 [Graphic] 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT L 
 VALIDATION PLAN 
 To be mutually agreed to by the
parties 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Contract Manufacturing Validation Checklist Pilot 3 
 BG Medicine Galectin-3 Test Kit 
 Project 09-001 
  

					
	 Requirement
	  	 Testing Plan
	  	 Status

	1. Manufacturing Documents and Processes:
			
	 1.1 [***]
	  	[***]	  	[***]
	 1.2 [***]
	  	[***]	  	[***]
	 1.3 [***]
	  	[***]	  	 [***]
 [***]

	 1.4 [***]
	  	[***]	  	[***]
	 1.5 [***]
	  	[***]	  	[***]
	 1.6 [***]
	  	[***]	  	[***]
	 1.7 [***]
	  	[***]	  	[***]
	 1.8 [***]
	  	[***]	  	 [***]
 [***]
 [***]

	 1.9 [***]
	  	[***]	  	[***]
	 1.10 [***]
	  	[***]	  	[***]
	 1.11 [***]
	  	[***]	  	[***]

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
	 Requirement
	  	 Testing Plan
	  	 Status

	 1.12 [***]
	  	[***]	  	 [***]
 [***]
 [***]
 [***]
 [***]
 [***]

	 1.13 [***]
	  	[***]	  	 [***]
 [***]

	 1.14 [***]
	  	[***]	  	[***]
	 2. Labels and Precautions:
	  		  	
	 2.1 [***]
	  	[***]	  	[***]
	 2.2 [***]
	  	[***]	  	[***]
	 2.3 [***]
	  	[***]	  	[***]
	 2.4 [***]
	  	[***]	  	[***]
	 2.5 [***]
	  	[***]	  	[***]
	 3. Vendors and Raw Materials:
	  		  	
	 3.1 [***]
	  	[***]	  	[***]
	 3.2 [***]
	  	[***]	  	[***]
	 3.3 [***]
	  	[***]	  	[***]
	 3.4 [***]
	  	[***]	  	[***]
	 3.5 [***]
	  	[***]	  	[***]
	 3.6 [***]
	  	[***]	  	[***]
	 3.7 [***]
	  	[***]	  	[***]
	 4. Validations:
	  		  	
	 4.1 [***]
	  	[***]	  	[***]
	 4.2 [***]
	  	[***]	  	[***]

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
	 Requirement
	  	 Testing Plan
	  	 Status

	 4.3 [***]
	  	[***]	  	[***]
	 4.4 [***]
	  	[***]	  	 [***]
 [***]
 [***]

	 4.5 [***]
	  	[***]	  	[***]
	 4.6 [***]
	  	[***]	  	[***]
	 4.7 [***]
	  	[***]	  	[***]
	 4.8 [***]
	  	[***]	  	[***]
	 4.9 [***]
	  	[***]	  	[***]
	 4.10 [***]
	  	[***]	  	[***]
	 4.11 [***]
	  	[***]	  	[***]
	 5. Shipping:
	  		  	
	 5.1 [***]
	  	[***]	  	[***]
	 5.2 [***]
	  	[***]	  	[***]
	 5.3 [***]
	  	[***]	  	[***]
	 6. Training:
	  		  	
	 6.1 [***]
	  	[***]	  	[***]
	 6.2 [***]
	  	[***]	  	[***]
	 6.3 [***]
	  	[***]	  	[***]
	 6.4 [***]
	  	[***]	  	[***]
	 6.5 [***]
	  	[***]	  	[***]
	 6.6 [***]
	  	[***]	  	[***]
	 7. Business Issues/Qualify Planning/Regulatory:
	  		  	
	 7.1 [***]
	  	[***]	  	[***]
	 7.2 [***]
	  	[***]	  	[***]
	 7.3 [***]
	  	[***]	  	[***]
	 7.4 [***]
	  	[***]	  	[***]

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Summary 
 [***] with [***]. [***] were [***] for [***] to [***]. [***] will be [***] by [***] and [***]. 
 The [***] were [***] for Pilot 3: 
 [***] 
 [***] 
 [***] 
 [***] 
 Also of note: 
 [***] 
 [***] 
 [***] 
 [***] 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Conclusion  
 [***] 
  

	1.	[***] 

	2.	[***] 

	3.	[***] 

	4.	[***] 

	5.	[***] 

 [***] 
 Additional changes to follow for test methods, excel worksheets, and TM worksheets to incorporate updated standard vial reconstitution instructions once
validated by BG Medicine. Reference attached PI revision. 
 Contract Manufacturing Validation Checklist Review: 
  

							
	 /s/ James Patzke
	  		  	Date: 2009-10-27	  	
	 BG Medicine Representative
	  		  		  	
				
	 /s/ Tammy Buckner
	  		  	Date: 2009-10-27	  	
	 Corgenix Representative
	  		  		  	

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Galectin-3 Pilot Raw Material Lot # Track 
  

											
	 P/N
	  	 Raw Material
	  	 Pilot 0
	  	 Pilot 1
	  	 Pilot 2
	  	 Pilot 3

	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  		  		  	
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT M 
 QUALITY AGREEMENT 
 To be mutually agreed to by the
parties 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Quality Agreement 
 Between 
 BG Medicine, Inc. (“BG
Medicine”) 
 And 
 Corgenix, Inc. (“Corgenix”) 
 A. Purpose: 
 To identify the shared and individual responsibilities (the “Shared and Individual Responsibilities”) between BG Medicine and Corgenix to ensure
compliance with applicable United States Food and Drug Administration (“FDA”) Good Manufacturing Practices (“GMP”/”QSr”) regulations, European Union (“EU”) requirements, for example, ISO 13485, and other
applicable regulations and to define the type, frequency and or content of quality metric (“Quality Metric(s)”) reports prepared by Corgenix for submission to BG Medicine in connection with manufacturing Product(s) as defined in that
certain Supply Agreement (the “Agreement”) executed between BG Medicine and Corgenix dated March 20, 2009. 
 B. Scope:

 Microtiter plate ELISA in vitro diagnostic test kits manufactured by Corgenix at its facility in Broomfield CO according to BG
Medicine specifications. 
 All capitalized terms not defined herein shall have the meanings ascribed to them in the Agreement. To the extent
any terms and conditions contained herein conflict with the Agreement, the terms and conditions of the Agreement shall take precedence and shall in all cases supercede any additional or different terms contained herein. 
 The contractual Agreement and this Quality Agreement are not disclosable to or subject to inspection by the FDA. Any sections of the Quality Reports that
contain information necessary to comply with § 820.20(c), Management Review, are also not disclosable to or subject to inspection by the FDA. Additionally, both BG Medicine and Corgenix will comply with its respective procedures governing
inspections by the FDA. 
 C. Responsibilities: 
 (1) BG Medicine and Corgenix agree to each appoint a quality representative (the “Representative(s)”). The Representative of BG Medicine shall be the Director of Quality Assurance or designee
and the Representative of Corgenix shall be the Quality Assurance/Regulatory Affairs Manager or designee. The Representatives or their designees shall meet in person or by teleconference from time to time or as needed. The Representatives

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
or their designees shall be responsible for overseeing, reviewing and recommending quality programs and reporting obligations with respect to the Quality Metrics and Shared and Individual
Responsibilities, including Technical Review Board (“TRB”) activities, if any, concerning the Product(s) provided in connection with the Agreement. 
 (2) BG Medicine and Corgenix agree to carry out their respective responsibilities and to procure and supply and cause contractors and vendors to procure and supply all goods and services provided in
connection with the Agreement in compliance, in all material respects, with the applicable provisions of FDA, EU and other applicable regulations as set forth in Schedule A attached. For responsibilities designated as shared in Attachment A, a
description of respective responsibilities is given below. 
 Title 21 of the CFR 
 §807, Establishment Registration—Both BG Medicine and Corgenix will maintain current Establish Registrations with the FDA.

 §801/ §809, Labeling—BG Medicine is responsible for all labeling content. BG Medicine will maintain
control of the Instructions for Use (IFU) and all promotional material within the BG Medicine document control system. BG Medicine will supply an approved copy of the IFU to Corgenix Quality Assurance. Corgenix Quality Assurance will maintain a
Master Copy of the current revision of the IFU on file for kit production purposes. Corgenix will prepare and control product labels within the Corgenix document control system with a BG Medicine representative as one of the approvers. 

§810, Recall—BG Medicine maintains overall responsibility for all recall activities, but Corgenix will assist with
retrieval of all distribution records and ensuring all nonconforming product at Corgenix is properly quarantined. 
 §806, Reports of Corrections & Removals—BG Medicine maintains overall responsibility for all corrections and removals, including reporting, but Corgenix will assist with retrieval of all distribution records and
ensuring all nonconforming product at Corgenix is properly quarantined. 
 §820.20, Management
Responsibility—Both BG Medicine and Corgenix will maintain a quality system in compliance with §820.20. 
 §820.22, Quality audit—Both BG Medicine and Corgenix will maintain a quality system in compliance with §820.22. 
 §820.25, Personnel—Both BG Medicine and Corgenix will maintain a quality system in compliance with §820.25. 
 §820.30, Design controls—Both BG Medicine and Corgenix will maintain a quality system in compliance with §820.30. BG
Medicine is responsible for Design Controls for

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
BG Medicine products, but may utilize the Corgenix document control system for design changes with BG Medicine as one of the approvers. A copy of any Corgenix records of such changes (e.g. change
orders) will be sent to BG Medicine for inclusion in the DHF. 
 § 820.40, Document control—Both BG Medicine and
Corgenix will maintain a quality system in compliance with § 820.40. 
 Change Control. Corgenix agrees to not make,
authorize or implement any change or modification to the Product(s) or its manufacturing processes without prior written approval by BG Medicine. 
 § 820.50, Purchasing controls—Both BG Medicine and Corgenix will maintain a quality system in compliance with § 820.50. BG medicine will be responsible for purchasing monoclonal
antibodies (M3/38 and 87B5-HRP) and arranging direct shipment of antibodies to Corgenix. Corgenix will be responsible for the receiving acceptance of the monoclonal antibodies (§ 820.80b) based on Corgenix Raw Material Specifications. Corgenix
will be responsible for qualifying suppliers by its Vendor Qualification procedures. However, in the case of suppliers that provide materials for only BG medicine, BG medicine will be responsible for site audits of the supplier if BG medicine
determines an audit is appropriate. 
 § 820.70, Production and process controls—Corgenix will be responsible
for implementation of production and process controls in compliance with § 820.70, however, BG Medicine will pre-approve all changes to production processes that affect the quality of BG Medicine Products, prior to implementation. 

§ 820.100, Corrective and Preventive Action—Both BG Medicine and Corgenix will maintain a quality system in compliance
with § 820.100. 
 Disposition of Nonconformances—Corgenix shall adhere to its quality system CAPA procedures and shall
input and analyze quality data sources and trends as part of the nonconformance investigation. Investigations shall attempt to determine the root cause of nonconformance, where possible. Nonconformances shall be evaluated with respect to all Product
quality attributes, and apply risk analysis and statistical methods, where necessary. Distribution of Product(s) shall be stayed until resolution or preventive steps, including validation, if necessary, are taken and agreed to in writing by BG
Medicine. In cases where the nonconformance is purely a system issue and has been shown through investigations to not adversely affect BG Medicine Product Quality, BG medicine notification and approval is not required. Nonconformance information
shall be submitted for management review. Nonconformance metrics shall be reported to BG Medicine according to the terms described in section C(3) of this Quality Agreement. Corgenix will notify BG Medicine of all planned deviations in the form of
Temporary Deviation Notices (TDN) and obtain written approval when said deviations may impact the Quality of BG Medicine Products. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 §820.180, Records, General requirements—Both BG Medicine and Corgenix will
maintain a quality system in compliance with §820.180. 
 §820.181, Device master record (DMR)—BG Medicine
will supply product specifications, production procedures and testing/inspection procedures to Corgenix for implementation in its production processes. Corgenix will prepare a DMR and obtain BG Medicine written approval via FAX or e-mail. The DMR
will be controlled within the Corgenix quality system. 
 §820.181, Quality system record—Both BG Medicine and
Corgenix will maintain a quality system in compliance with §820.181. 
 §820.198 , Complaint
files—BG Medicine will provide all Complaint Handling services and will maintain complaint files in compliance with § 820.198. When requested by BG Medicine, Corgenix will perform product quality investigations in support of BG Medicine
complaint handling efforts. The investigations will occur and results communicated back to BG Medicine in a timely manner taking into consideration the importance of the investigation. Corgenix will make every effort to supply at least a preliminary
report to BG Medicine within a week from receiving a request from BG Medicine to undertake an investigation. In particular the reporting of product quality investigations must allow BG Medicine to comply with the reporting requirements of §
803, Medical Device Reporting. All records of the investigation including a summary of the results will be forwarded to BG Medicine for inclusion in the complaint file. During Corgenix product quality investigations, if a failure is confirmed, a
Nonconformance Report will be initiated. 
 §820.250, Statistical techniques—Both BG Medicine
and Corgenix will maintain a quality system in compliance with §820.180. 
 (3) Periodic Quality Reports content and frequency. Corgenix
agrees to submit periodic reports on Quality Metrics with respect to BG Medicine products according to the frequency given in Schedule B attached hereto and incorporated herein as a part of this Quality Agreement. The content of such reports shall
be in the form of quality data input as given in Schedule B and shall be applied starting with the first lot accepted for commercial distribution. 
 (4) Cooperation. BG Medicine and Corgenix agree to cooperate in resolving nonconformances, complaints and other quality issues arising during the manufacture of the Product(s) under the Agreement and to collaborate in performing any
investigation or testing and in taking any necessary corrective action to resolve the same. The Representatives or their designees shall be responsible for ensuring appropriate investigation of the cause of any significant event and shall determine
report obligations under Quality Metrics. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

									
	 SO AGREED:
	  		  		  	
				
	 BG Medicine, Inc.
	  		  		  	
					
	 By:
	  	 /s/ James Patzke
	  		  	Date: 2009-06-18	  	
	 Name:
	  	James Patzke	  		  		  	
	 Title:
	  	Director of Quality Assurance	  		  		  	
				
	 Corgenix, Inc.
	  		  		  	
					
	 By:
	  	 /s/ Daniel Simpson
	  		  	Date: 2009-06-18	  	
	 Name:
	  	Daniel Simpson	  		  		  	
	 Title:
	  	QA/RA Manager	  		  		  	

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 SCHEDULE A 
 SHARED & INDIVIDUAL RESPONSIBILITIES 
  

					
	 General Controls of the FD&C Act, as codified at Title 21 of the CFR
	  	 Responsible Party

	 	  	 BG Medicine
	  	 Corgenix

	 § 807 Establishment Registration
	  	ü	  	ü
	 § 807 Device Listing
	  	ü	  	-
	 §801/ §809 Labeling
	  	ü	  	ü
	 §810 Recall
	  	ü	  	ü
	 §806 Reports of Corrections & Removals
	  	ü	  	ü
	 §803 Medical Device Reporting (MDR)
	  	ü	  	-
		
	 Tariff Act of 1930 & U.S. Customs Service Regulations, as codified at Title 19 of the
CFR
	  	 
			
	 §134 Country of Origin Marking
	  	ü	  	-
		
	 USDA Regulations, Animal & Plant Inspection Service, codified at Title 9 of the CFR
	  	 
			
	 §§93-96 BSE (Import)
	  	ü	  	-

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
	 GMP/QSr Regulation1

	  	 Responsible Party

	  	 BG Medicine
	  	 Corgenix

	 § 820.20—Management responsibility
	  	ü	  	ü
	 § 820.22—Quality audit
	  	ü	  	ü
	 § 820.25—Personnel
	  	ü	  	ü
	 § 820.30—Design controls
	  	ü	  	ü
	 § 820.40—Document controls
	  	ü	  	ü
	 § 820.50—Purchasing controls
	  	ü	  	ü
	 § 820.60—Identification
	  	-	  	ü
	 § 820.65—Traceability
	  	-	  	ü
	 § 820.70—Production and process controls
	  	ü	  	ü
	 § 820.72—Inspection, measuring, and test equipment
	  	-	  	ü
	 § 820.75—Process validation
	  	-	  	ü
	 § 820.80—Receiving, in-process, and finished device acceptance
	  	-	  	ü
	 § 820.86—Acceptance status
	  	-	  	ü
	 § 820.90—Nonconforming product
	  	-	  	ü
	 § 820.100—Corrective and preventive action (CAPA)
	  	ü	  	ü
	 § 820.120—Device labeling
	  	-	  	ü
	 § 820.130—Device packaging
	  	-	  	ü
	 § 820.140—Handling
	  	-	  	ü
	 § 820.150—Storage
	  	-	  	ü
	 § 820.160—Distribution
	  	-	  	ü

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
	 GMP/QSr Regulation1

	  	Responsible Party
	  	BG Medicine	  	Corgenix
	 § 820.170—Installation
	  	NA	  	NA
	 § 820.180—Records, General requirements
	  	ü	  	ü
	 § 820.181—Device master record (DMR)
	  	ü	  	ü
	 § 820.184—Device history record (DHR)
	  	-	  	ü
	 § 820.186—Quality system record
	  	ü	  	ü
	 § 820.198—Complaint files
	  	ü	  	-
	 § 820.200—Servicing
	  	NA	  	NA
	 § 820.250—Statistical techniques
	  	ü	  	ü

  

	1	 The corresponding ISO13485:2003 requirement will be evident in each Quality System, as applicable. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 SCHEDULE B 
 QUALITY METRICS AND QUALITY REPORT CONTENTS 
  

			
	 Parameter/Quality Data Input
	  	 Report
 Frequency

	 Supplier evaluation and monitoring status for BG Medicine products including a summary of supplier nonconformances and any
resulting supplier CAPAs.
	  	Quarterly
		
	 Number of component, raw materials lots rejected or accepted for BG Medicine Products.
	  	Quarterly
		
	 Number of Finished Products Accepted and Rejected for BG Medicine Products.
	  	Quarterly
		
	 Technical Review Board activities for BG Medicine products; number of items accepted, rejected and pending, sub-categorized by
design, supplier, manufacturing, storage and distribution.
	  	Quarterly
		
	 Product Yield (# of kits accepted/# of kits started) for BG Medicine Products.
	  	Quarterly
		
	 Number of CAPA/nonconformances opened and closed, sub-categorized by design, supplier, manufacturing, storage and distribution
for BG Medicine Products.
	  	Quarterly
		
	 Number of product quality investigations in support of BG Medicine complaint handling open and completed, including time to
completion, in days for BG Medicine Products.
	  	Quarterly
		
	 Number of total change controls, sub-categorized by design, raw material (components), labeling, manufacturing, storage and
distribution changes for BG Medicine products.
	  	Quarterly
		
	 Status of internal audits involving BG Medicine products
	  	Quarterly

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.First Amendment to Lease Agreement

 Exhibit 10.43 
 FIRST AMENDMENT TO LEASE 
 This FIRST AMENDMENT TO LEASE (“First
Amendment”) is made this 29th day of January, 2010 by and between Cypress Court Operating Associates, Limited Partnership, a New Mexico limited partnership (“Landlord”) and Southern Bay Energy, L.L.C., a Texas limited
liability company (“Tenant”). 
 RECITALS: 
 WHEREAS, Landlord and Tenant entered into that certain Lease Agreement dated September 25, 2008 covering certain leased premises (“Leased Premises”) containing 13,755 square feet of Net
Rentable Area in Suite 220 and Suite 225 on the second floor of the building commonly known as Cypress Court (“Building”) located at 110 Cypress Station Drive in Houston, Harris County, Texas; and 
 WHEREAS, the Lease Agreement and this First Amendment, including any and all exhibits, addenda, riders, estoppels and letter agreements, shall hereinafter
be collectively referred to as the “Lease Agreement”; and 
 WHEREAS, Tenant desires to extend the term of the Lease Agreement and
expand the Leased Premises; and Landlord and Tenant further agree to amend the Lease to reflect same; 
 AGREEMENTS: 

NOW, THEREFORE, for and in consideration of the sum of ten and no/100 dollars ($10.00) and other valuable consideration paid by each party to the other,
the receipt and sufficiency of which is hereby acknowledged, Landlord and Tenant do hereby amend the Lease Agreement as follows: 
 1. Leased
Premises. Effective on the Leasehold Improvements Completion Date (as defined below), the Leased Premises, as defined in the Lease Agreement, shall be increased from 13,755 square feet of Net Rentable Area to 15,809 square feet of Net Rentable
Area (See Exhibit “A” attached hereto and incorporated herein). 
 2. Leasehold Improvements. The Leased Premises shall be
delivered to Tenant and Tenant shall accept same, in its current “AS IS, WHERE IS” condition subject to the construction of leasehold improvements, if any, set forth and described on Exhibit B attached hereto and made
a part hereof for all purposes. Tenant acknowledges that no representations as to the repair of the Leased Premises or the Building, nor promises to alter, remodel or improve the Leased Premises or the Building, have been made by Landlord, except as
are expressly set forth in this Lease Agreement. 
 3. Term. The term of this Lease Agreement (the “Term”) shall be 60
months and shall commence on the Leasehold Improvements Completion Date , which is anticipated to be May 1, 2010 (the “Leasehold Improvements Completion Date”), less the total number of days of

 
Tenant Delay (as defined on Exhibit B) (such date being herein referred to as the “Commencement Date”) and, unless sooner terminated or renewed and extended in
accordance with the terms and conditions set forth herein, shall expire at 11:59 p.m. on April 30, 2015 (the “Expiration Date”). 
 4. Base Rent. The Base Rent for the “Leased Premises” shall be payable in monthly installments, on or before the first day of each month as follows: 
  

										
	 Months Following the
 Commencement Date
	  	Annual Base Rent Rate Per
Square Foot of Net Rentable Area	  	Annual Base Rent	  	Monthly Payment
	 1-12
	  	$	13.50	  	$	213,421.56	  	$	17,785.13
	 13-24
	  	$	14.00	  	$	221,325.96	  	$	18,443.83
	 25-36
	  	$	14.50	  	$	229,230.48	  	$	19,102.54
	 37-48
	  	$	15.00	  	$	237,135.00	  	$	19,761.25
	 49-60
	  	$	15.50	  	$	245,039.52	  	$	20,419.96

 5. Additional Rent / Operating
Expenses. As of the Effective Date, the “Premises” shall have a Proportionate Share of 16.55% which is the percentage obtained by dividing (i) Tenant’s rentable Square Feet by (ii) the total Rental Square Feet in the
Building and shall have a Base Year of 2010. 
 6. Exhibit C. – Parking Agreement. Landlord hereby agrees to make available to
Tenant during the full Term of this First Amendment, seven (7) reserved parking spaces and fifty-five (55) unreserved parking spaces (hereinafter collectively referred to as the “Parking Spaces”) on the Building surface
parking lot (hereinafter referred to as the “Surface Lot”), upon the terms and conditions set forth in Exhibit C of the Lease Agreement. 
 7. Termination Option. Section 52 of the Lease Agreement is hereby deleted in its entirety and replaced with the following language: 
 A. Subject to and upon the terms, provisions and conditions set forth in this Section 7, Tenant shall have the
option (the “Termination Option”) to terminate this Lease Agreement effective on the last day of the thirty-sixth (36th) month of the Term (the “Early Termination Date”). In order to exercise the Termination Option,
Tenant must (i) give Landlord written notice of its exercise of the Termination Option not later than four (4) months prior to the Early Termination Date and (ii) concurrently with the delivery of such notice, pay the Termination Fee
(as hereinafter defined) to Landlord. If Tenant fails to give notice of exercise of the Termination Option by such deadline, such Termination Option shall be deemed waived and of no further force and effect. If Tenant gives notice of exercise of the
Termination Option by such deadline but fails to pay the Termination Fee to Landlord, Landlord may at its option either (i) deem the Termination Option waived and of no further force and effect or (ii) enforce the termination of this Lease
Agreement, effective as of such Early Termination Date, and Tenant’s obligation to pay the Termination Fee. The provisions of this Section 7 shall survive the expiration or termination of this Lease Agreement. 

 B. The “Termination Fee” shall be an amount equal to the sum of the
unamortized portion of the Lease Costs (as hereinafter defined) as of the relevant Early Termination Date. For purposes of calculating the Termination Fee, each component or item of Lease Costs will be deemed to be amortized in equal monthly
installments over the period beginning with the Commencement Date and continuing through the end of the Term, amortized at a ten percent (10%) annual percentage rate. “Lease Costs” means the (i) out-of-pocket costs
incurred by Landlord in connection with the Leasehold Improvements, (ii) the leasing commissions and reasonable legal fees incurred by Landlord in connection with the execution of this Lease Agreement and (iii) all construction costs,
architectural and engineering fees, leasing commissions, reasonable legal fees, relocation reimbursements and other costs incurred by Landlord in connection with Tenant’s lease of any preferential space or other additional space in the Building
after the execution of this Lease Agreement. 
 C. The Termination Option may be exercised by Tenant only if, at the time of
such exercise and on the relevant Early Termination Date, no event of default exists (unless Landlord, in its sole discretion, elects to waive such condition). If such condition is communicated to, but not cured by, Tenant (unless waived by
Landlord), the Termination Option shall be deemed waived by Tenant, and any purported exercise thereof shall be null and void. 
 8.
Right of First Refusal: 
 A. Subject only to the renewal options, expansion options, rights of first offer and
rights of first refusal of other tenants in the Building granted by Landlord prior to the Effective Date or which are included in any lease executed after the Effective Date as to which Tenant failed or elected not to exercise its right of refusal
under this Section 8, Tenant shall have a continuing right of first refusal (the “Right of First Refusal”) during the Term with respect to any available space in the Building that is contiguous to the Leased Premises
(“ROFR Space”). 
 B. In the event Landlord desires to accept an offer to lease any of the ROFR Space from any
third party (a “Lease Offer”), as evidenced by a term sheet or letter of intent, signed by the third party prospect (subject to any confidentiality requirements of such third party prospect prohibiting disclosure of its name),
Landlord shall give Tenant written notice thereof (the “Availability Notice”), which notice shall include the Lease Offer. If such Availability Notice is delivered to Tenant, Tenant shall have ten (10) days from the date of
receipt of the Availability Notice to either (i) irrevocably elect to lease said space under the Terms of the Lease Offer, by delivering written notice thereof (the “Election Notice”) to Landlord within such ten (10) day
period, or (ii) notify Landlord that it does not desire to lease said space. In the event Tenant (i) notifies Landlord that it does not desire to lease said space or (ii) fails to deliver the Election Notice to Landlord within said
ten (10) day period, Tenant shall be deemed to have elected not to lease said space, and Landlord shall have a period of ninety (90) days thereafter to lease such ROFR Space to such third party tenant prospect upon the terms set forth in
the Availability Notice, except that (i) the space actually leased may be ten percent (10%) greater or less than that set forth in the Lease Offer, and (ii) the lease may be different from the Lease Offer in other immaterial respects.
If Landlord does not enter into such a lease of such ROFR Space with such third party tenant prospect within said ninety (90) day period, or if Landlord desires to enter into a lease of the ROFR Space with another party or with such third party
tenant prospect in which

 
(i) the space actually leased is more than ten percent (10%) greater or less than the square footage specified in the Availability Notice or (ii) the lease terms vary in respects
that are material (such as the addition of an early termination provision) or decrease the rent or other economic obligations of the tenant reflected in the Lease Offer, Tenant shall again have a right of refusal on such ROFR Space as set forth in
this Section 8. 
 C. If Tenant exercises a Right of First Refusal, then effective as of the date that is the earlier to
occur of (1) the date Tenant occupies all or any portion of the ROFR Space for the purpose of conducting its business therein and (2) sixty (60) days following the date Landlord delivers possession of the ROFR Space to Tenant (the
“ROFR Space Delivery Date”), such ROFR Space shall become a part of the Leased Premises, the annual Base Rent per square foot of Net Rentable Area for such ROFR Space shall be equal to the Base Rent stated in the Lease Offer, and
such ROFR Space shall be subject to all of the terms, provisions and conditions of this Lease Agreement, except for any terms, covenants and conditions that are expressly or by their nature inapplicable to such ROFR Space, except that (i) Base
Rent and Tenant’s Additional Rent with respect to such ROFR Space shall commence to accrue on the earlier to occur of (1) the date Tenant occupies all or any portion of such ROFR Space for the purpose of conducting its business therein and
(2) sixty (60) days after Landlord’s delivery of the ROFR Space to Tenant, (ii) such ROFR Space and any and all leasehold improvements therein will be provided in the condition they exist (i.e. “AS IS” and
“WITH ALL FAULTS”) on such delivery date; and (iii) the Term of this Lease Agreement insofar as it relates to such ROFR Space shall be equal to the longer of (i) the Term with respect to the Leased Premises or (ii) the term
set forth in the Availability Notice. This Lease Agreement shall be deemed to have been automatically amended in accordance with this Section 50.C as of the date of the Election Notice, and Tenant and Landlord shall thereafter promptly (but in
no event longer than fifteen (15) days after Landlord’s submission of the amendment to Tenant) execute and deliver an appropriate amendment of this Lease Agreement to evidence the foregoing. 
 D. Notwithstanding any provision herein to the contrary, Tenant shall not have the right to lease the ROFR Space pursuant to this
Section 8 if, at the time Tenant exercises such Right of First Refusal or on the applicable ROFR Space Delivery Date, Tenant is in default under this Lease Agreement beyond any applicable notice and cure period. Any termination of this Lease
Agreement shall also terminate the Right of First Refusal. Tenant shall not have the right to assign the Right of First Refusal to any subtenant of the Leased Premises or assignee of this Lease Agreement, nor may any such subtenant or assignee
exercise such Right of First Refusal. 
 Except as modified and amended herein, all other terms and conditions of the Lease Agreement are hereby
ratified and affirmed in all respects. 

 IN WITNESS WHEREOF, Landlord and Tenant, acting herein by duly authorized individuals, have caused these
presents to be executed in multiple counterparts, each of which shall have the force and effect of an original on this 29th day of January, 2010 (the “Effective Date”). 
  

									
	LANDLORD:	 		 	TENANT:
			
	 CYPRESS COURT OPERATING
 ASSOCIATES, LIMITED PARTNERSHIP
	 		 	SOUTHERN BAY ENERGY, L.L.C.
					
	By:	 	BGK Cypress Court LLC, General Partner	 		 		 	
					
	By:	 	 /s/ J. Peter Mehlert
	 		 	By:	 	 /s/ Howard E. Ehler

	Name:	 	J. Peter Mehlert	 		 	Name:	 	 Howard E. Ehler

	Title:	 	 President, BGK Texas Property Mgmt, LLC as Agent For
	 		 	Title:	 	 Vice President-Chief Financial Officer

 EXHIBIT A 
 FLOOR PLAN OF THE LEASED PREMISES 

 

 

 Lease 
 Premises

 15,809 SF of 
 NRA 

 EXHIBIT B 
 LEASEHOLD IMPROVEMENTS 
 1. Work by Landlord.
Landlord shall cause to be constructed and/or installed in the Leased Premises the permanent leasehold improvements and tenant finish more particularly described in those certain plans attached hereto as Exhibit B-1 through B-4 (the
“Leasehold Improvements”). The leasehold construction will be performed by a general contractor of Landlord’s choice. 
 2. Planning and Construction. Landlord and Tenant shall cooperate in good faith in the planning and construction of the Leasehold Improvements, and Tenant shall respond promptly to any request from
Landlord or Landlord’s architect or contractor for Tenant’s approval of any particular aspect thereof, it being agreed and understood that it is the intent and desire of the parties that the Leased Premises be ready for Tenant’s
occupancy on or before the Estimated Leased Premises Delivery Date. 
 3. Quality of Work. Landlord shall supervise the
construction of the Leasehold Improvements and shall use its diligent good faith efforts to cause same to be constructed and installed in a good and workmanlike manner in accordance with good industry practice. 
 4. Completion of Construction. The “Leasehold Improvements Completion Date” shall mean the date upon which the
Leasehold Improvements are substantially complete. The phrase “substantially complete” shall mean that all construction debris has been removed from the Leased Premises and the Leased Premises are reasonably clean, the Leased
Premises may reasonably be used and occupied for the purposes intended by the Tenant and the progress of the construction of the Leasehold Improvements to date is such that final completion of the Leasehold Improvements can occur within a reasonable
period of time and without undue interference to the Tenant’s use of the Leased Premises. If the Leased Premises are not ready for occupancy by the Estimated Leased Premises Delivery Date for any reason, Landlord shall not be liable or
responsible for any claims, damages or liabilities in connection therewith or by reason thereof. 
 5. Tenant Delay. As
used herein, “Tenant Delay” shall mean the sum of (i) the number of days of delay in responding to Landlord’s request for approval of any documentation in connection with the Leasehold Improvements, (ii) the number of
days of delay in preparing any of such documentation caused by changes requested by Tenant to any aspect of the Leasehold Improvements which were reflected in the documentation theretofore approved by Tenant, and (iii) the positive difference,
if any, between the increase and decrease in the number of days required to complete the Leasehold Improvements caused by changes requested by Tenant to the working drawings after Tenant’s approval thereof. 
 6. Disclaimer of Warranty. TENANT ACKNOWLEDGES THAT THE CONSTRUCTION AND INSTALLATION OF THE LEASEHOLD IMPROVEMENTS WILL BE
PERFORMED BY AN UNAFFILIATED CONTRACTOR OR CONTRACTORS AND THAT ACCORDINGLY LANDLORD HAS MADE AND WILL MAKE NO WARRANTIES TO TENANT WITH RESPECT TO THE QUALITY OF CONSTRUCTION THEREOF OR AS TO THE CONDITION OF THE LEASED PREMISES, EITHER EXPRESS OR
IMPLIED, AND THAT LANDLORD EXPRESSLY DISCLAIMS ANY IMPLIED WARRANTY THAT THE LEASED PREMISES ARE OR

 
WILL BE SUITABLE FOR TENANT’S INTENDED COMMERCIAL PURPOSE. AS SET FORTH IN SECTION 27 OF THIS LEASE, TENANT’S OBLIGATION TO PAY BASE AND ADDITIONAL RENTAL HEREUNDER IS NOT DEPENDENT
UPON THE CONDITION OF THE LEASED PREMISES OR THE BUILDING OR THE PERFORMANCE BY LANDLORD OF ITS OBLIGATIONS HEREUNDER, AND TENANT SHALL CONTINUE TO PAY THE BASE AND ADDITIONAL RENT WITHOUT ABATEMENT, SETOFF OR DEDUCTION, NOTWITHSTANDING ANY BREACH
BY LANDLORD OF ITS DUTIES OR OBLIGATIONS HEREUNDER, WHETHER EXPRESS OR IMPLIED. However, Landlord agrees that in the event that any defect in the construction of the Leasehold Improvements are discovered, Landlord will diligently pursue and seek
to enforce any warranties of the contractor(s) and/or the manufacturer of any defective materials incorporated therein. 
 7. Cost of Leasehold Improvements. Landlord shall pay all costs and expenses of the Leasehold Improvements (including but not limited to, all labor, materials, architectural and engineering costs, permits reports and construction and
occupancy certificates). 

 EXHIBIT B-1 
 LEASEHOLD IMPROVEMENTS 

 

 

 EXHIBIT B-2 
 LEASEHOLD IMPROVEMENTS 

 

 

 EXHIBIT B-3 
 LEASEHOLD IMPROVEMENTS 

 

 

 EXHIBIT B-4 
 LEASEHOLD IMPROVEMENTS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]